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Introduction  
1.1 Introduction to Solid Dispersions: 
[1]
 
 
As early as in 1961, Sekiguchi et al. developed the concept of solid dispersion to 
enhance absorption of poorly water-soluble drugs. It involved formation of eutectic mixtures 
of drugs with water-soluble carriers by melting of their physical mixtures, and once the 
carriers dissolved, the drug precipitated in a finely divided state in water. Later, Goldberg et 
al. demonstrated that a certain fraction of the drug may also be molecularly dispersed in the 
matrix, forming solid solutions, while other investigators reported that the drug may be 
embedded in the matrix as amorphous materials. On the basis of these considerations, Chiou 
and Riegelman defined solid dispersion as ―the dispersion of one or more active ingredients 
in an inert excipient or matrix, where the active ingredients could exist in finely crystalline, 
solubilized, or amorphous states.‖ 
                                                    
 
 
Flow Chart: Advantages of a solid dispersion formulation, as compared to conventional 
capsule or tablet formulations, for enhancing dissolution rate, and consequent bioavailability 
of poorly water-soluble drugs. 
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Need of Solid Dispersion: 
[1, 3] 
Compared to conventional tablet and capsule dosage forms, solid dispersion 
formulations are relatively complex drug delivery systems, requiring a substantially greater 
commitment of time, effort, and resources for development.  
Therefore, whether there is a need for solid dispersion and whether the desired 
bioavailability enhancement will not be achieved by other relatively less complex techniques 
such as particle size reduction or salt formation, should be assessed by careful in-vitro 
assessment of the NCE‘s biopharmaceutical properties and the relevance of these findings to 
the projected in-vivo formulation performance.  
Horter and Dressman defined a poorly water-soluble drug as one for which the 
dissolution time of a single dose in the GI fluids exceeds the normal transit time through the 
absorptive regions of the GIT.   
Hence, the absorption of poorly water-soluble compounds is dose dependent and 
controlled by the dissolution rate in the GIT and solubility in GI fluids. The fraction of the 
dose absorbed will decrease with an increase in the dose size if the drug particle size or 
surface area is held constant, while, on the other hand, if the dose size is held constant, the 
fraction of the dose absorbed will increase with a reduction in particle size or an increase in 
the particle surface area.   If it is determined that complete absorption of the dose 
might be obtained by reducing the particle size, for instance, to approximately 2–5µm (within 
the range of standard manufacturing capability), a conventional tablet or capsule dosage form 
may still be feasible.  
However, if it is determined that particle size reduction to the submicron range is 
necessary; a solid dispersion may provide a viable alternative. In silico absorption modeling 
with software packages, such as Gastro Plus® (Simulations Plus, Lancaster, California), have 
demonstrated utility in determining the impact of particle size reduction on drug absorption. 
Advantages: 
- Processing equipment available at small and large scale 
- Thermolabile products 
- Most carriers can act as ―solid‖ solvent 
- Carriers (mainly surface active agents) can maintain super saturation in GI tract 
- Downstream processing is possible 
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Disadvantages: 
- Understanding the physics of amorphous materials 
- Understanding the physical structure of solid dispersions 
- Understanding the relationship between physical structure and drug release 
- Stability issues; residual solvents 
- Prediction of shelf life of amorphous materials 
- Increasing number of drugs with low solubility in organic solvents 
- Few new carriers  
Preparation Methods: 
Fusion Method: 
[14] 
The fusion method is sometimes referred to as the melt method, which is correct only 
when the starting materials are crystalline. Therefore, the more general term fusion method is 
preferred. The first solid dispersions created for pharmaceutical applications were prepared 
by the fusion method.  
The dispersion consisted of sulfathiazole and urea as a matrix which were melted 
using a physical mixture at the eutectic composition, followed by a cooling step. The eutectic 
composition was chosen to obtain simultaneous crystallization of drug and matrix during 
cooling. 
 This procedure resulted in solid dispersions of type I. PEG (Poly ethylene glycol) is a 
hydrophilic polymer often used to prepare solid dispersions with the fusion method. This 
often results in solid dispersions of type III since many drugs are incorporated as separate 
molecules in the helical structure present in a crystalline PEG. The helices are aligned in 
orderly fashion, illustrating that PEG easily crystallizes. Another polymer frequently applied 
as a matrix in the fusion method is PVP (polyvinyl pyrollidone).  PVP, supplied in the 
amorphous state, is heated to above its Tg (Glass transition temperature).  
The drug has to fuse with or dissolve in the rubbery matrix, which is subsequently 
cooled to vitrify the solid dispersion. When PVP is used as matrix, solid dispersions of type V 
or VI are obtained. 
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The mode of incorporation of the drug depends on the PVP-drug miscibility and the 
preparation procedure. Grinding is required to obtain the solid dispersion as powder that is 
easy to handle. 
Although frequently applied, the fusion method has serious limitations. Firstly, a 
major disadvantage is that the method can only be applied when drug and matrix are 
compatible and when they mix well at the heating temperature. When drug and matrix are 
incompatible two liquid phases or a suspension can be observed in the heated mixture, which 
results in an inhomogeneous solid dispersion. 
This can be prevented by using surfactants. Secondly, a problem can arise during 
cooling when the drug-matrix miscibility changes. In this case phase separation can occur. 
Indeed, it was observed that when the mixture was slowly cooled, crystalline drug occurred, 
whereas fast cooling yielded amorphous solid dispersions. Thirdly, degradation of the drug 
and or matrix can occur during heating to temperatures necessary to fuse matrix and drug. 
 For example, to melt a sugar matrix of galactose a temperature of 169°C was required 
and in order to get the glassy PVP in the rubbery state a temperature of about 170°C is 
required. PEG‘s melted at around 70°C and are therefore often used for the preparation of 
solid dispersions with the fusion method. 
Hot melt extrusion: 
[14] 
Melt extrusion is essentially the same as the fusion method except that intense mixing 
of the components is induced by the extruder. When compared to melting in a vessel, the 
product stability and dissolution are similar, but melt extrusion offers the potential to shape 
the heated drug-matrix mixture into implants, ophthalmic inserts, or oral dosage forms. Just 
like in the traditional fusion process, miscibility of drug and matrix can be a problem.  
Solubility parameters are investigated to predict the solid-state miscibility and to 
select matrices suitable for melt extrusion. High shear forces resulting in high local 
temperatures in the extruder be a problem for heat sensitive materials. However, compared to 
the traditional fusion method, this technique offers the possibility of continuous production, 
which makes it suitable for large-scale production. Furthermore, the product is easier to 
handle because at the outlet of the extruder the shape can be adapted to the next processing 
step without grinding. 
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Fig-2 
Solvent evaporation method: 
[14] 
The first step in the solvent evaporation method is the preparation of a solution 
containing both matrix material and drug. The second step involves the removal of solvent(s) 
resulting in formation of a solid dispersion. Mixing at the molecular level is preferred, 
because this leads to optimal dissolution properties. Using the solvent method, the 
pharmaceutical engineer faces two challenges. The first challenge is to mix both drug and 
matrix in one solution, which is difficult when they differ significantly in polarity. To 
minimize the drug particle size in the solid dispersion, the drug and matrix have to be 
dispersed in the solvent as fine as possible, preferably drug and matrix material are in the 
dissolved state in one solution. 
Various strategies have been applied to dissolve the lipophilic drug and hydrophilic 
matrix material together in one solution. Low drug concentrations are used to dissolve both 
drug and matrix material in water, but this requires evaporation of tremendous amounts of 
solvent, making the process expensive and impractical. Solubilisers like cyclodextrins or 
surfactants like Tween80
®
 increase the aqueous solubility of the drug substantially.  
However, the amounts of solubilisers or surfactants in the final product are often 
eminent. This results in solid dispersions that, to a significant extent, consist of solubilisers or 
surfactants, materials that significantly change the physical properties of the matrix (e.g. 
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decrease of Tg). Moreover, only dosage forms with low drug loads are possible. In addition, 
they are not always tolerated well in the body or may even be toxic. Chloroform or 
dichloromethane have been used to dissolve both drug and PVP as matrix simultaneously. 
 These solvents are used also in other preparation methods. However, according to the 
ICH-Guidelines, these solvents belong to Class I, comprising the most toxic solvents. 
Therefore, the use of these solvents is unacceptable and impractical because the amount of 
residual solvent present in the solid dispersion after drying has to be below the detection 
limits. The last strategy for the dissolution of both drug and matrix is the use of solvent 
mixtures. Water and ethanol, or dichloromethane and ethanol have been used for this 
purpose.  
However, dissolution of drug and matrix in these mixtures is not always possible in 
the required concentration or ratio. The second challenge in the solvent method is to prevent 
phase separation, e.g. crystallization of either drug or matrix, during removal of the 
solvent(s). Drying at high temperatures speeds up the process and reduces the time available 
for phase separation. On the other hand, at high temperatures the molecular mobility of drug 
and matrix remains high, favouring phase separation (e.g. crystallization). 
To dry the solutions, vacuum drying is often used. The solution is dried by the 
application of vacuum and moderate heating. Sometimes, the solvent evaporation is 
accelerated by using a rotary evaporator. Afterwards the formed solid dispersion is often 
stored in a vacuum desiccator to remove the residual solvent. Vacuum drying at elevated 
temperature bears the risk of phase separation because the mobility of drug and matrix 
decreases slowly.  
Another drying technique is spray drying. The solution is dispersed as fine particles in 
hot air. Due to the large specific surface area offered by the droplets, the solvent rapidly 
evaporates and the solid dispersion is formed within seconds, which may be fast enough to 
prevent phase separation. Moreover, the solid dispersions prepared by spray drying consist of 
particles of which the size may be customized by changing the droplet size to meet the 
requirements for further processing or application (e.g. free flowing particles or particles for 
inhalation). Spray drying usually yields drug in the amorphous state, however sometimes the 
drug may have (partially) crystallized during processing. 
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An alternative to these drying techniques is freeze drying. Although it is concluded in 
literature that this is a promising and suitable technique to incorporate drug substances in 
stabilizing matrices, the technique is poorly exploited for the preparation of solid dispersions. 
One of the reasons might be the low freezing temperature of most organic solvents. 
Obviously, sublimation during freeze drying is only possible when the solvent stays frozen. 
 In addition when the formation of a glass is envisaged, the sample temperature 
should be kept below the Tg of the maximally freeze concentrated fraction. Therefore, low 
sample temperatures are required which slows down the process. Betageri and Makarla used 
a condenser temperature of -75°C, to dry a solution with cyclohexanol as the solvent. In table 
6 an overview is presented of several organic solvents. To obtain a lyophilization process of 
acceptable duration, the solvent should have a sufficiently high vapour pressure. As can be 
seen in table 6, dimethylsulphoxide DMSO has a high melting temperature but it has a very 
low vapour pressure. Therefore, DMSO is not suitable as a solvent for freeze drying. 
A suitable solvent that meets both requirements is 2-methyl-2-propanol or tertiary 
butanol (TBA), because it has a high melting temperature as well as a high vapour pressure. 
The application of TBA in lyophilization is discussed by Teagarden. Also mixtures of 
solvents can be considered. However, in that case the phase diagram of the mixture should be 
consulted. For example, while water and DMSO have melting points of 0°C and 19°C, the 
mixture has eutectic points below -60°C. The sample temperature of such a mixture should be 
kept below this value, which causes a slow sublimation. 
An important advantage of freeze drying is that the drug is subjected to minimal thermal 
stress during the formation of the solid dispersion. However, the most important advantage of 
freeze drying is that the risk of phase separation is minimized as soon as the solution is 
vitrified. 
An even more promising drying technique is spray-freeze drying. The solvent is sprayed into 
liquid nitrogen or cold dry air and the frozen droplets are subsequently lyophilized. The large 
surface area and direct contact with the cooling agent result in even faster vitrification, 
thereby decreasing the risk for phase separation to a minimum. Moreover, spray freeze drying 
offers the potential to customize the size of the particle to make them suitable for further 
processing or applications like pulmonary or nasal administration. 
Spray Drying: 
[14] 
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Spray drying is a process where a solution of drug substance and carrier is evaporated 
by spraying the solution as a droplet into a chamber that is maintained under controlled 
conditions of heat, humidity, and air flow. The dissolution rate of many poorly water-soluble 
drugs has been enhanced using spray drying.  
Organic solvents are normally used during spray-drying process as they are easy to 
evaporate and possess good solvent capacity for many poorly water-soluble drugs. The 
morphology form of solid dispersion, and consequently the drug dissolution and stability, can 
be impacted by the process parameters and geometry of equipment. For instance, the particle 
size of spray-dried solid dispersion can be controlled by varying the concentration of solute in 
spray-drying liquid and the droplet size during spray-drying process. 
 
Fig-3 
Supercritical fluid methods: 
[15] 
Supercritical fluid methods are mostly applied with carbon dioxide (CO2), which is 
used as either a solvent for drug and matrix or as an anti-solvent. When supercritical CO2 is 
used as solvent, matrix and drug are dissolved and sprayed through a nozzle, into an 
expansion vessel with lower pressure and particles are immediately formed. The adiabatic 
expansion of the mixture results in rapid cooling. This technique does not require the use of 
organic solvents and since CO2 is considered environmentally friendly, this technique is 
referred to as ‗solvent free‘. The technique is known as Rapid Expansion of Supercritical 
Solution (RESS). However, the application of this technique is very limited, because the 
solubility in CO2 of most pharmaceutical compounds is very low (<0.01wt-%) and decreases 
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with increasing polarity. Therefore, scaling up this process to kilogram-scale will be 
impractical. 
All other supercritical techniques are precipitation methods. Although generally 
labelled as solvent-free, all these supercritical fluid methods use organic solvents to dissolve 
drug and matrix and exploit the low solubility of pharmaceutical compounds in CO2. In fact, 
these techniques represent alternative methods to remove solvents from a solution containing 
typically a drug and a polymer. Moneghini and co-workers reported their method as solvent-
free, but they dissolved PEG and carbamazepine in acetone. They used a technique that is 
called the Gas-Anti-Solvent technique (GAS) or Precipitation from Gas Saturated Solutions 
(PGSS). The solution is brought into contact with compressed CO2. The conditions are 
chosen so that CO2 is completely miscible with the solution under supercritical conditions, 
whereas drug and matrix will precipitate upon expansion of the solution. When the volume of 
the solution expands the solvent strength (i.e. the ability to dissolve the drug) decreases. This 
results in precipitation of matrix and drug. Since this technique is often applied with PEG as 
matrix, this technique results in formation of a solid dispersion with a crystalline matrix 
(mostly type II or III). 
The second type of precipitation technique involves the spraying of a solution 
containing drug and matrix through a nozzle into a vessel that contains a liquid or 
supercritical anti-solvent. The supercritical anti-sol droplets, in which drug and matrix 
become supersaturated, crystallize and form particles. The general term for this process is 
Precipitation with Compressed Anti- Solvent (PCA). More specific examples of PCA are 
Supercritical Anti Solvent (SAS) when supercritical CO2 is used, or Aerosol Solvent 
Extraction System (ASES), and Solution Enhanced Dispersion by Supercritical fluids 
(SEDS).  
However, as with the other solvent techniques described in the previous section, the 
critical step in these precipitation techniques might be the dissolution of drug and matrix in 
one solution. The use of water is limited, because the water solubility in compressed CO2 is 
limited. Usually organic solvents like dichloromethane or methanol have to be applied to 
dissolve both drug and matrix. 
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Other methods: 
Evaporative precipitation into aqueous solutions (EPAS) was used to coat a colloidal 
suspension of carbamazepine with block-copolymers as stabilizing surfactants. A solution of 
drug in dichloromethane was sprayed in an aqueous solution containing polymeric surfactants 
as stabilizers. The obtained colloidal suspension was spray dried, freeze dried or spray freeze 
dried, resulting in solid dispersions of type IV/V. It was concluded that the amorphous state 
of the drug was best preserved with the spray freeze drying process. 
In another process called supercritical fluid impregnation, the drug is dissolved in a 
supercritical fluid and exposed to solid matrix material that swells and absorbs the 
supercritical solution. By varying the pressure and the time of exposure, the diffusion process 
can be controlled. The absorption stops when the pressure is reduced. This process is 
investigated for polymethyl methacrylate but can be applied for other polymers as well. 
In an electrostatic spinning process a drug-matrix solution is pumped through an 
orifice and then subjected to an electrical field to form fibres with a diameter of micro- or 
nano-scale. This process is restricted to a limited amount of matrices, because only a few 
high molecular weight materials are fibre forming materials. The fibre diameter can be 
adjusted by surface tension, electrical field and dielectric constant. After rapid evaporation of 
the solvent, the fibres can be directly used or milled and further processed. 
Carriers:
 [11, 13] 
Selection criteria for polymeric carriers: 
- High Tg 
- Super saturation potential 
- screening studies from DMSO, DMF in aqueous carrier solutions 
- Possibility of interactions with drug 
- Solid state solubility (miscibility) of drug in the carrier (molecular dispersion) 
- phase behavior studies (―one Tg‖) films 
- Theoretical models (e.g. Flory-Huggins) 
- Solubility in monomers (e.g. NMP) 
- Ternary phase diagrams 
- Solubility in water (organic solvents depending on manufacturing process) 
- manufacturing process. 
Introduction 
 
Department of Pharmaceutics, Nandha College of Pharmacy, Erode. Page 11 
 
Type of carriers: 
Sugars: Dextrose, Sucrose, galactose, Sorbitol, Maltose, Xylitol, Mannitol, lactose. 
Acids: Citric acid, Succinic acid. 
Poymeric Materials: Povidone, PVP, PEG, HPMC, Methyl Cellulose, HEC, Cyclo dextrins, 
HPC, Pecttin. 
Insoluble and Enteric Polymers: HPMC phthalate, Eudragit L-100, Eudragit S-100, Eudragit 
RL, and RS. 
Surfactants: Polyoxy Etthylene Stearate, Renex poloxamer 188, Texafor AIP, Deoxycholic 
acid, Tweens, Spans. 
Miscellaneous: Penta erithrytol, Penta erithryl tetra acetate, Urea, Urethane, Hydroxy alkyl 
Xanthins. 
Current Trends in Solid dispersions: 
[2] 
In recent years due to application of combinational chemistry and high-throughput 
screening during drug discovery, a majority of new drug candidates exhibits poor aqueous 
solubility, compounds to be very challenging for formulation scientists in development of 
bioavailable dosage forms for such. 
A poorly water soluble compound has classically been defined as one dissolving in 
less than 1part per 10000 part of water.
 
A poorly water soluble drug, more recently, has been 
defined in general terms to require more time to dissolve in the gastrointestinal fluid than it 
take to be absorbed in the gastrointestinal tract. Thus a greater understanding of dissolution 
and absorption behaviors of drugs with low aqueous solubility is required to successfully 
formulate them into bioavailable drug products. 
Although salt formation, particle size reduction, etc. have commonly been used to 
increase dissolution rate of the drug, there are practical limitation with these techniques the 
desired bioavailability enhancement may not always be achieved. Therefore formulation 
approaches are being explored to enhance bioavailability of poorly water-soluble drugs. One 
such formulation approach that has been shown to significantly enhance absorption of such 
drugs is to formulate/prepare solid dispersion. 
Chiou and Riegelman defined the term solid dispersion as “a dispersion involving 
the formation of eutectic mixtures of drugs with water soluble carriers by melting of 
their physical mixtures”. 
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The term solid dispersion refers to the dispersion of one or more active ingredient in 
an inert carrier or matrix at solid state prepared by melting (fusion), solvent, or the melting 
solvent method. Sekiguchi and Obi suggested that the drug was present in a eutectic mixture 
in a microcrystalline state, after few years Goldberg et.al. Reported that all drug in solid 
dispersion might not necessarily be presents in a microcrystalline state, a certain fraction of 
the drug might be molecular dispersion in the matrix, thereby forming a solid solution. 
 Once the solid dispersion was exposed to aqueous media & the carrier dissolved, the 
drug was released as very fine, colloidal particles. Because of greatly enhanced surface area 
obtained in this way, the dissolution rate and the bioavailability of poorly water-soluble drugs 
were expected to be high. The commercial use of such systems has been limited primarily 
because of manufacturing problems with solid dispersion systems may be overcome by using 
surface active and self-emulsifying carriers. The carriers are melted at elevated temperatures 
and the drugs are dissolved in molten carriers. 
Surface-active agents are substances that at low concentrations adsorb onto the 
surfaces or interfaces of a system and alter the surface or interfacial free energy and the 
surface and the interfacial tension. Surface-active agents have a characteristic structure, 
possessing both polar (hydrophilic) and non-polar (hydrophobic) regions in the same 
molecule. The surface active carriers are said to be amphipathic in nature. 
 
Surface active carriers uses in Pharmaceutical preparation: 
[9] 
Because of their unique functional properties, surface active carriers find a wide range 
of uses in pharmaceutical preparations. These include, depending on the type of product, 
improving the solubility or stability of the drug in the liquid preparation, stabilizing and 
modifying the texture of semisolid preparations, or altering the flow properties of the final 
tablet dosage form.    In addition to their use as excipients to improve the physical and 
chemical characteristics of the formulation, surface active carriers may be included to 
improve the efficacy or the bio performance of the product.  
The properties of surfactant are such that they can alter the thermodynamic activity, 
solubility, diffusion, disintegration, and dissolution rate of a drug. Each of these parameters 
influences the rate and extent of drug absorption. Furthermore, surface active carriers can 
exert direct effects on biological membranes thus altering drug transport across the 
membrane. 
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The advantage of a surface-active carrier over a non-surface-active one in the 
dissolution of drug from a capsule formulation is shown schematically in Figure below. The 
physical state of drug if a solid dispersion must, however, is carefully considered an 
evaluating the advantage of a surface-active vehicle. As mentioned earlier, the drug can be 
molecularly dispersed in the carrier to form a solid solution or it can be dispersed as particles. 
It can also be both partially dissolved and partially dispersed in the carrier.  
The potential for the formation of a continuous drug rich surface layer is possibly 
greater if the drug is molecularly dispersed, whereas the drug dispersed, as particulates may 
be more prone to dissociation from the water-soluble matrix. It is however, rare that the drug 
is dispersed just as particulates and is not at least partially dissolved in the vehicle. Therefore, 
a surface-active carrier is preferably in almost all cases for the solid dispersion of poorly 
water-soluble drugs. 
 
Figure: 4 A schematic representation of the comparative dissolution of a poorly water-
soluble drug from surface-active versus non surface-active vehicle. 
Block Copolymers as Pharmaceutical Surface active carriers: 
The toxicity of many pharmaceutical surface active carriers has led to the search of 
more acceptable solubilizers. Soluble surface-active block copolymers of polyoxyethylene 
and polyoxypropylene have been used widely in pharmaceuticals and significantly found 
favor for such critical applications as emulsifiers for intravenous lipids and as priming agents 
for heart lung apparatus.  
A range of commercial block copolymer surface active carriers are available under the 
Pluronic, Pluronic R, Tetronic, and pluradot trade names; their preparation and properties 
have been reviewed by schmolka. The corresponding nonproprietary names of the first three 
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types are Poloxamer, Meroxapols and Poloxamine, respectively, there being no equivalent 
name for the plurodot compounds. 
Poloxamers are polyoxyethylene-polyoxypropylene-polyoxyethylene (ABA) block 
copolymers; The Meroxapols are polyoxypropylene-polyoxyethylene- polyoxypropylene 
(BAB) copolymers; The Poloxamine structure, (AB)2NCH2CH2N(BA) 2, is in full form as 
below. 
[H (C2H4O) a (C3H6O) b]2NCH2CH2N[(C3H6O)b (C2H4O)aH]2 
The Poloxamers have been most widely studied to date, yet there has been 
considerable confusion in the literature over the exact nature of their colloidal behavior, in 
particular whether micelles are formed. Recently, surface tension measurement on a series of 
Poloxamers in aqueous solution and photon correlation spectroscopy has helped to resolve 
some of these problems, but as benefits their structure their behavior patterns tend to be 
complex.  
At low concentrations, approximating those at which more conventional nonionic 
detergents form micelles, the Poloxamers monomers are thought to form monomolecular 
micelles by a change in configuration in solution. At higher concentration these 
monomolecular micelles associate to form aggregates of varying size, which have the ability 
to solubilize drugs and to increase the stability of solubilized agents. 
 
Figure: 5 Schematic representations of block and random copolymer micelles 
 
The solubilities of some Para substituted acetanilide in aqueous Poloxamers solutions 
increase with increasing ox ethylene content of the polymer, although the more hydrophobic 
solutes do not show this trend. The results show that, e.g., 4-nitroacetanilide is less soluble in 
more hydrophilic Poloxamers, and this is the general trend shown by the halogenated 
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derivatives. Pluronic F68 solubilizes some benzocaine, which above an apparent CMC of 
0.23% w/v has a slope for the solubility curve K, of 0.019, i.e., S= SO + K (Csurfactant - CMC) 
=SO +0.019(Csurfactant – CMC). The order for solubilization of benzocaine is Triton WR1339 
(a tert-octylphenol with ethylene oxide) > Brij 35 > Tetronic 908 > Pluronic F68. At 3% 
levels the half-life of benzocaine is increased 4 times by Brij 35 and triton WR1399, but the 
limited solubility of benzocaine in Pluronic solutions results in only a marginal increase in 
half-life. Pluronic F68 lowers blood viscosity and has been advocated. Intravenous 
administration of Pluronic F38 is followed by rapid excretion in the urine; F68 appears in bile 
to the extent of 6% of the injected IV dose. Poloxamers 108 (Pluronic F38), although rapidly 
phagocytosed, is well tolerated even when administered intravenously in large doses. 
Pluronic block copolymers are synthesized by sequential polymerization of propylene 
oxide and ethylene oxide. It consists of combined chain of oxyethylene with oxy propylene 
where oxyethylene impart hydrophillicity whereas oxypropylene impart lipophilicity. Each 
molecule is synthesized as long segment of the hydrophilic portion combined with long 
segment of hydrophobic portion referred to as block copolymer. A defining property of 
Pluronic is ability of individual block copolymer molecules termed as ―unimers‖ to self-
assemble into micelles in aqueous solution.  
The ―unimers‖ form a molecular dispersion in water at block copolymer 
concentrations below the critical micelle concentration. At concentration above CMC, the 
unimers molecule aggregate, forming micelles with propylene oxide bock in the inner core of 
micelles covered by the hydrophilic corona from ethylene oxide block. The water insoluble 
compounds are transpired into the propylene core of the micelles. 
Block copolymer micelles are aggregates that resemble many properties of micelles 
formed by low molecular weight surface active carriers. They are the consequence of a self-
assembling tendency displayed by block copolymers when dissolved in a so-called selective 
solvent, which is a good solvent for one of the blocks, but a poor one for the other. Solvent 
selectivity and, hence, copolymer self-assembling, have been observed for a variety of block 
copolymers in water, polar and non-polar organic solvents and, more recently, in supercritical 
fluids.  
For this generality and for the possibility of tuning the aggregate properties by 
varying either the kind of monomer or the size and proportion of the constituting blocks, 
these aggregates are able to provide a much wider range of applications than that observed 
for normal surface active carriers, involving solubilization of drugs or pollutants, as 
nonreactors, in controlled drug delivery and as potential DNA carriers, among others. 
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Limitations of Surface active carrier based Solid Dispersions: 
[9] 
Solid dispersion in surface-active carriers may not be the answer to all bioavailability 
problems with poorly water-soluble drug. One of the limitations of bioavailability 
enhancement by this method might be the low solubility of drug in available carriers. The 
desired dose of a drug cannot be solubilized and filled into the hard gelatin capsules if 
adequate solubility in a carrier cannot be obtained. 
 Dordunoo et al
 
reported that the particle size of a drug in a solid dispersion remained 
unchanged if it is just mixed with the carrier instead of dissolving in it. On the other hand, if 
the drug is dissolved by heating in excess of its solubility in a carrier under normal storage 
condition, it may subsequently crystallize out from the solid dispersion. Either situation 
would defect the purpose of bioavailability enhancement of poorly water-soluble drugs by 
solid dispersion. 
Another possible limitation of the use of surface-active carrier reported by Aungst et 
al.
 
is that the bioavailability of a drug may vary depending on the amount of carrier 
administered along with it. This variation is because different amounts of a surface-active 
carrier may have different solubilization or dispersion effects on a drug in the gastrointestinal 
fluid. Serajuddin et al. reported a method whereby the rate and efficiency of dispersion of 
drug in aqueous media from different formulations can be studied. 
Hydrophilic Polymers: 
 Polymers like PEG, PVP, UREA has become extremely popular in controlling the 
release rate of drugs from solid dosage forms. When a matrix containing a swellable glassy 
polymer comes into contact with a solvent, a progressive alteration from the glassy to the 
rubbery state leads to a swelling process. For matrix system, drug is often released by 
diffusion, because a sort of receding drug boundary comes to exist within the system. 
Hydroxypropylmethylcellulose (HPMC) is non-ionic aqueous-soluble cellulose ether 
derivative for use in controlled-release dosage forms. Owing to high swellability and high 
gelling strength formation this polymer effectively prolongs drug release, which has a 
significant effect on the release kinetics of an incorporated drug.
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Newer techniques:  
The two important breakthrough in formulation of solid dispersion are, the 
development of technologies to fill solid dispersions directly in to hard gelatin capsule and 
the ability of surface active & self-emulsifying agents carriers. The technique to fill solid 
dispersion directly into hard gelatin capsule as melts, which gets solidify at room 
temperature, was first described by Francol‘s & Jones in 1978. But the potential application 
of that technique was fully realized by Chatham. For ease of manufacturing the carriers must 
be amenable to liquid filling into hard gelatin capsules as melts. The melting temperature of 
carriers should be such that the solutions do not exceed ~70°C which is the maximum 
acceptable temperature for hard gelatin capsule shells. 
The water soluble carriers dissolves more rapidly than the drug, the drug rich layer 
has to form over the surface of dissolving plug, which prevent further dissolution of drug 
from solid dispersion because of this directly filled hard gelatin capsule is not a good method 
of preparation of solid dispersion unless the formation of drug rich layer on the surface of 
dissolving plug can be prevented. 
The self-emulsifying agent will act as dispersing or self –emulsifying agent on drug 
through which the dissolution of drug can be increase by preventing the formation of any 
water insoluble surface layer, although the liberated drug remain un dissolved in the 
dissolution medium. When its concentration exceeded its saturation solubility, it will disperse 
or emulsify into a finely divided state because of the surface activity of the dissolved vehicle 
the high surface area will be made available which will facilitate its dissolution in 
gastrointestinal fluid.  
Serajuddin et al. has also studied improve dissolution of dispersions of REV-5901. He 
prepared solid dispersion of poorly water-soluble REV-5901 (alpha-pentyl-3- (2-
quinolinylmethoxy) benzene methanol) in various PEG‘s & in Gelucire® 44/14 filled in to 
hard gelatin capsule, Gelucire
® 
44/14
 
formulation were able to promote complete & rapid 
drug dispersion in water & simulated gastric fluid. The PEG‘s formulations by contrast were 
only effective in achieving partial drug dispersion. When the formulation with Gelucire
® 
44/14 can be filled into soft gelatin capsule without any change in solubilization 
characteristic of REV-5901 conversely the formulation with PEG-400 gives rise to drug 
crystallization due to water migration from the gelatin envelop to the fill, which lead to a 
45% reduction in REV-5901 solubility. 
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The most commonly used surface-active carrier is Gelucire
® 
44/14 & other grades of 
Gelucire
® 
the carriers are prepared to have a high melting point but not more than 70 C so as 
to compatible to be filled in hard gelatin capsule. The grades of Gelucire
® 
denote different no 
like Gelucire
® 
44/14, Gelucire
® 
50/13 in that first digit denote the melting point of carrier and 
second digit denote HLB value of carrier, on which the grades are differentiated & used as 
per for its different applications. Gelucire
® 
44/14 is a mixture of glyceryl & PEG-1500 ester 
of long-chain fatty acid & is official in European pharmacopoeia as a lauryl 
macrogolglycerides. 
Dordunoo et al studied the effect of Gelucire
® 
44/14 for improving the solubility of 
Temazepam in comparison with various PEG‘s & found Gelucire® 44/14 has shown large 
increase in its water solubility. Dordunoo et al has also studied the comparative dissolution of 
the hard gelatin capsule contain 12.5% of Triamterene dispersion in various PEG‘s or in 
Gelucire
® 
44/14 with that of capsule containing the drug alone. The result of dissolution 
studies shown that dissolution of Triamterene without excipients was limited up to 30% only 
& with Gelucire
® 
44/14 or PEG-1000 was found to be 100% of active ingredient in less than 
an hour. 
For in-vivo study Aungst B.J. et al & his co-worker has work on improvement of oral bio-
availability of an HIV Protease inhibitor using Gelucire
® 
44/14 & Labrasol vehicle. 
DMP-323 is an HIV-Protease inhibitor exhibiting poor water solubility (< 10 
micrograms /ml.). Aungst et al measured the apparent solubility of DMP-323 in aqueous 
dispersion of Gelucire
® 
44/14 or PEG-400 as a function of excipients concentration Gelucire
® 
clearly improved the apparent solubility of drug while PEG-400 had no solubilization effect 
on the drug. 
Chen et al improved the dissolution and bioavailability of ABT-963, a poorly water-soluble 
compound by preparing solid dispersion using Pluronic F-68 as a carrier by evaporation and 
hot melt method. The results show that solid dispersion is a promising approach for 
increasing oral bioavailability. 
Passerini et al prepared granules containing Ibuprofen, a poorly soluble model drug 
by melt granulation. The aim was to improve dissolution and its availability; using lactose as 
a diluent and Poloxamer 188 (Lutrol F68) as a new metastable hydrophilic binder. In the 
conclusion, it was suggested that melt granulation technique is an easy and a fast method to 
improve the dissolution rate of ibuprofen, using Poloxamer 188 as a new hydrophilic 
metastable binder. 
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Vippagunta et al characterized the nature and solid state properties of solid dispersion 
system of Nifedipine in a polymer matrix consisting of Pluronic F 68 and Gelucire 50/13 in 
1:1:1 ratio. The results indicate that the Nifedipine solid dispersion is physically stable. The 
release of Nifedipine was faster in solid dispersion than pure crystalline drug of the same 
particle. 
 
Table: 1 Examples of surface-active carriers used for dissolution enhancement. 
S. No. Carrier Drug Scientist 
1. Poloxamer 188 Ibuprofen Passerini et al 
2. Poloxamer 188 ABT-963 Chen et al 
3. Poloxamer 407 Nifedipine Chutinawarapan et al 
4. 
Poloxamer 188, Gelucire 
50/13 
Nifedipine Vippagunta et al 
5. Gelucire 44/14 REV 5901 Sheen et al 
6. Gelucire 44/14 LAB-687 Serajuddin et al 
7. 
Mixture Gelucire 44/14-
lecithin 
Ubidecarenone Pozi et al 
8. 
Gelucire 44/14 and PEG 
6000 
Glibenclamide Tashtoush 
9. 
Gelucire 44/14, Vitamin E 
TPGS 
Carbamazepine Squillanate et al 
10. 
Gelucire, Capmul, Capmul 
MCM C10 
Ceftriaxone 
Seong-Wan CHO et 
al 
11. Polyethylene glycol DMP 323 Aungst et al 
12. 
Mixture of Gelucire 50/13, 
Polysorbate 80, Polyox 
Ritonavir --- 
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Future Prospects: 
[15] 
Despite many advantages of solid dispersion, issues related to preparation, 
reproducibility, formulation, scale up, and stability limited its use in commercial dosage 
forms for poorly water-soluble drugs. Successful developments of solid dispersion systems 
for preclinical, clinical and commercial use have been feasible in recent years due to the 
availability of surface-active and self-emulsifying carriers with relatively low melting points. 
The preparation of dosage forms involves the dissolving of drugs in melted carriers and the 
filling of the hot solutions into gelatin capsules. 
 Because of the simplicity of manufacturing and scale up processes, the 
physicochemical properties and as expected to change significantly during the scale up. For 
this reason, the popularity of the solid dispersion systems to solve difficult bioavailability 
issues with respect to poorly water-soluble drugs will grow rapidly. Because the dosage form 
can be developed and prepared using small amounts of drugs substances in early substances 
in early stages of the drug development process, the system might have an advantage over 
such other commonly used bioavailability enhancement techniques as micronization of drugs 
and soft gelatin encapsulation. 
One major focus of future research will be identification of new surface-active 
carriers and self-emulsifying carriers for solid dispersion. Only a small number of such 
carriers are currently available for oral use. Some carriers that are used for topical application 
of drug only may be qualified for oral use by conducting appropriate toxicological testing. 
One limitation in the development of solid dispersion system may be the inadequate drug 
solubility in carriers, so a wider choice will increase the success of dosage form development. 
 Research should also be directed toward identification of vehicles or excipients that 
would retard or prevent crystallization of drugs from supersaturated systems. Attention 
should also be given to any physiological and pharmacological effects of carriers used. Many 
of the surface-active and self-emulsifying carriers are lipid in nature, so potential roles of 
such carriers on drug absorption, especially on their p-glycoprotein-mediated drug efflux, 
will require careful consideration. In addition to bioavailability enhancement, much recent 
research on solid dispersion systems was directed towards the development of extended-
release dosage forms. It may be pointed out that this area of research has been reinvigorated 
by the availability of surface-active and self-emulsifying carriers and the development of new 
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capsule filling processes. Because the formulation of solid dispersion for bioavailability 
enhancement and extended release of drugs may employ essentially similar processes, except 
for the use of slower dissolving carriers for the later use, it is expected that the research in 
these two areas will progress simultaneously and be complementary to each other. 
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Introduction to HIV / AIDS 
Introduction: 
[4, 5] 
Drugs which are active against human immune deficiency virus (HIV) which is a 
retro virus. These are useful in prolonging and improving the quality of life and postponing 
complications of acquired immune deficiency syndrome (AIDS) or AIDS related complex 
(ARC), but do not cure the infection. The clinical efficiency is monitored primarily by plasma 
HIV – RNA assays and CD4 lymphocyte count carried out at regular intervals. 
Classification: 
1) Nucleoside reverse transcriptase inhibitors ( NRTI’S): 
 Zidovudine, Didanosine, Stavudine, Lamivudine. Are the drugs comes under 
this classification. 
2) non – nucleoside reverse transcriptase inhibitors: 
 Nevirapine, Efavirenz. Are the drugs comes this under classification.  
3) retroviral protease inhibitor (PI’S): 
 Indinavir, Neflinavir, Saquinavir, Ritonavir, Lopinavir. Are the drugs comes 
this under classification. 
Mechanism of action:  
 Retroviral protease inhibitors: 
 Lopinavir: 
 
 An aspartic protease enzyme encoded by HIV is involved in the 
production of structural proteins and enzymes (including reverse 
transcriptase) of the virus. 
 The large viral poly protein in broken into various functional 
components by this enzyme. 
 This protease acts as a late step in HIV replication, i.e. Maturation of 
the new virus particles when the RNA genomes acquire the core 
proteins and enzymes. 
 These protease inhibitors bind to protease molecule, interfere with its 
cleaving function and acts at late step of viral life cycle. 
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 Under the influence of both newly and chronic infected cells HIV – 
infected cells produce immature noninfectious viral progeny. This 
leads to viral replication prevention.   
 
Symptoms: 
         
 Dizziness 
 Mood changes 
 Depression 
 Anxiety 
 Paraxoia 
 Fatigue 
 Weakness 
 Frequent urination 
 Increased thirst 
 Nausea and vomiting 
 Additional pain 
 Tiredness 
 Abnormal heart beat 
 Weight loss 
 Jaundice 
 Fever 
 tuberculosis 
Pathophysiology: 
[5] 
        Cells affected: 
The virus entering through which ever route, acts primarily on following cells 
       Lymph reticular system: 
                                                   CD4 T – helper, Macrophages, Monocytes, β- Lymphocytes, 
Certain endothelial cells 
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        Central nervous system: 
Microglia of nervous system, Astrocytes, Oligodendrocytes, Neurons. 
Diagnosis:  
WHO: 
Stage – I: HIV infection is a symptomatic and not categorized as AIDS. 
Stage – II: 
Includes minor mucocutaneous manifestations and recurrent upper respiratory tract 
infection. 
Stage – III: 
Includes unexplained chronic diarrhea for longer than a month, severe bacterial 
infections and pulmonary tuberculosis. 
Stage – IV: 
Includes toxoplasmosis of the brain, candidiasis of the esophagus, trachea, 
bronchi/lungs and kaposis sarcoma. These diseases are indicators of AIDS. 
Antibody tests: 
HIV Antibody tests are specifically designed for routine diagnostic testing of adults; 
these tests are inexpensive and extremely accurate. 
Window period 
Antibody tests may give false negative (no antibodies were detected despite the 
presence of HIV) results during the window period, an interval of three weeks to six months 
between the time of HIV infection and the production of measurable antibodies to 
HIV seroconversion. Most people develop detectable antibodies approximately 30 days after 
infection, although some seroconvert later. The vast majority of people (97%) have detectable 
antibodies by three months after HIV infection; a six-month window is extremely rare with 
modern antibody testing. During the window period, an infected person can transmit HIV to 
others although their HIV infection may not be detectable with an antibody 
test. Antiretroviral therapy during the window period can delay the formation of antibodies 
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and extend the window period beyond 12 months. This was not the case with patients that 
underwent treatment with post exposure prophylaxis (PEP). Those patients must take ELISA 
tests at various intervals after the usual 28 day course of treatment, sometimes extending 
outside of the conservative window period of 6 months. Antibody tests may also yield false 
negative results in patients with X-linked agammaglobulinemia; other diagnostic tests should 
be used in such patients. 
Three instances of delayed HIV seroconversion occurring in health-care workers have 
been reported; in these instances, the health-care workers tested negative for 
HIV antibodies greater than 6 months post exposure but were seropositive within 12 months 
after the exposure. DNA sequencing confirmed the source of infection in one instance. Two 
of the delayed seroconversions were associated with simultaneous exposure to hepatitis 
C virus (HCV). In one case, co-infection was associated with a rapidly fatal HCV disease 
course; however, it is not known whether HCV directly influences the risk for or course 
of HIV infection or is a marker for other exposure-related factors. 
ELISA: 
The enzyme-linked immunosorbent assay (ELISA), or enzyme immunoassay (EIA), 
was the first screening test commonly employed for HIV. It has a high sensitivity. 
In an ELISA test, a person's serum is diluted 400-fold and applied to a plate to which 
HIV antigens have been attached. If antibodies to HIV are present in the serum, they may 
bind to these HIV antigens. The plate is then washed to remove all other components of the 
serum. A specially prepared "secondary antibody" — an antibody that binds to human 
antibodies is then applied to the plate, followed by another wash. This secondary antibody is 
chemically linked in advance to an enzyme. Thus the plate will contain enzyme in proportion 
to the amount of secondary antibody bound to the plate. A substrate for the enzyme is 
applied, and catalysis by the enzyme leads to a change in color or fluorescence. ELISA 
results are reported as a number; the most controversial aspect of this test is determining the 
"cut-off" point between a positive and negative result. 
Western blot: 
 Like the ELISA procedure, the western blot is an antibody detection test. However, 
unlike the ELISA method, the viral proteins are separated first and immobilized. In 
subsequent steps, the binding of serum antibodies to specific HIV proteins is visualized 
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Specifically, cells that may be HIV-infected are opened and the proteins within are 
placed into a slab of gel, to which an electrical current is applied. Different proteins will 
move with different velocities in this field, depending on their size, while their electrical 
charge is leveled by a surfactant called sodiumlaurylsulfate. Some commercially prepared 
Western blot test kits contain the HIV proteins an already on a cellulose acetate strip. Once 
the proteins are well-separated, they are transferred to a membrane and the procedure 
continues similar to an ELISA: the person's diluted serum is applied to the membrane and 
antibodies in the serum may attach to some of the HIV proteins. Antibodies that do not attach 
are washed away, and enzyme-linked antibodies with the capability to attach to the person's 
antibodies determine to which HIV proteins the person has antibodies. 
There are no universal criteria for interpreting the western blot test: The number of 
viral bands that must be present may vary. If no viral bands are detected, the result is 
negative. If at least one viral band for each of the GAG, POL, and ENV gene-product groups 
is present, the result is positive. The three-gene-product approach to western blot 
interpretation has not been adopted for public health or clinical practice. Tests in which less 
than the required number of viral bands is detected are reported as indeterminate: a person 
who has an indeterminate result should be retested, as later tests may be more conclusive. 
Almost all HIV-infected persons with indeterminate western blot results will develop a 
positive result when tested in one month; persistently indeterminate results over a period of 
six months suggest the results are not due to HIV infection. In a generally healthy low-risk 
population, indeterminate results on western blot occur on the order of 1 in 5,000 patients: 
However for those individuals that have had high-risk exposures to individuals where HIV-2 
is most prevalent, Western Africa, an inconclusive western blot test may prove infection with 
HIV-2. 
The HIV proteins used in western blotting can be produced by recombinant DNA in a 
technique called recombinant immunoblot assay (RIBA) 
Rapid or point-of-care tests: 
Rapid antibody tests are qualitative immunoassays intended for use as a point of care 
test to aid in the diagnosis of HIV infection. These tests should be used in conjunction with 
the clinical status, history, and risk factors of the person being tested. The positive predictive 
value  of Rapid Antibody Tests in low-risk populations has not been evaluated. These tests 
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should be used in appropriate multi-test algorithms designed for statistical validation of rapid 
HIV test results. 
If no antibodies to HIV are detected, this does not mean the person has not been 
infected with HIV. It may take several months after HIV infection for the antibody response 
to reach detectable levels, during which time rapid testing for antibodies to HIV will not be 
indicative of true infection status. For most people, HIV antibodies reach a detectable level 
after two to six weeks. 
Although these tests have high specificity, false positives do occur. Any positive test result 
should be confirmed by a lab using the western blot. 
Home Access Express HIV-1 Test It is the only FDA-approved home test: the patient 
collects a few blood drops from a finger stick, and mails the sample to a laboratory; results 
and counseling are obtained over the phone. All results are anonymous and confirmed before 
they are released. 
OraQuick is an antibody test that provides results in 20 minutes. The blood, plasma or oral 
fluid is mixed in a vial with developing solution, and the results are read from a sticklike 
testing device. Usually detects HIV 1 and HIV 2. 
Orasure is an HIV test that uses mucosal transudate from the tissues of cheeks and gums. It 
is an antibody test that first employs ELISA, then western blot. 
Uni-Gold is a rapid HIV antibody test that provides results in 10–12 minutes. A drop of 
blood is placed on the device with developing solution. Uni-Gold is only FDA approved to 
test for HIV 1. 
Clear view Complete HIV 1/2 and Clear view HIV 1/2 Stat-Pak are rapid tests for the 
detection of HIV 1 and HIV 2 antibodies in blood, serum, or plasma samples. Results are 
provided within 15 minutes. 
There is also a urine test; it employs both the ELISA and the western blot techniques. 
I Diagnostics Rapid HIV Test is, according only to their website, a non-FDA-approved 
home test. The company sells a blood test and a urine test produced by Intec PRODUCTS, 
INC. Similar to a home pregnancy test the patient collects a drop of blood/urine and drops the 
sample onto a cassette. Results are read visually in 15 minutes. The accuracy of this test has 
not been confirmed by the FDA, and it is not authorized for sale in the United States. 
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The INSTI HIV-1/HIV-2 Rapid Antibody Test is a rapid in vitro qualitative test for the 
detection of antibodies to Human Immunodeficiency Virus Type 1 in human whole blood, 
serum or plasma. The test is intended for use by trained personnel in medical facilities, 
clinical laboratories, emergency care situations, and physicians' offices as a screening assay 
capable of providing test results in less than 60 seconds. The assay is packaged as a kit 
containing INSTI Membrane Units, Sample Diluent, Color Developer and Clarifying 
Solution, and is available in point-of-care use packaging, or packaging suitable for laboratory 
use. 
Reveal HIV is a rapid in vitro qualitative test for the detection of antibodies to HIV in whole 
blood, serum or plasma. Reveal is among the fastest rapid HIV test available and it detects 
signs of early infection better than some other rapid tests. Reveal HIV is approved in Canada, 
the United States, Europe, Africa, Asia, and South America.
 
Interpreting antibody tests: 
ELISA testing alone cannot be used to diagnose HIV, even if the test suggests a high 
probability that antibody to HIV-1 is present. In the United States, such ELISA results are not 
reported as "positive" unless confirmed by a Western Blot. 
The ELISA antibody tests were developed to provide a high level of confidence that 
donated blood was NOT infected with HIV. It is therefore not possible to conclude that blood 
rejected for transfusion because of a positive ELISA antibody test is in fact infected with 
HIV. Sometimes, retesting the donor in several months will produce a negative ELISA 
antibody test. This is why a confirmatory Western Blot is always used before reporting a 
"positive" HIV test result. 
Rare false positive results due to factors unrelated to HIV exposure are found more 
often with the ELISA test than with the Western Blot. False positives may be associated with 
medical conditions such as recent acute illnesses and allergies. A rash of false positive tests in 
the fall of 1991 was initially blamed on the influenza vaccines used during that flu season, 
but further investigation traced the cross-reactivity to several relatively non-specific test 
kits. A false positive result does not indicate a condition of significant risk to health. When 
the ELISA test is combined with Western Blot, the rate of false positives is extremely low, 
and diagnostic accuracy is very high (see below). 
HIV antibody tests are highly sensitive, meaning they react preferentially with HIV 
antibodies, but not all positive or inconclusive HIV ELISA tests mean the person is infected 
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by HIV. Risk history, and clinical judgment should be included in the assessment, and a 
confirmation test (Western blot) should be administered. An individual with an inconclusive 
test should be re-tested at a later date. 
Antigens test: 
The p24 antigen test detects the presence of the p24protein of HIV (also known as 
CA), the capsid protein of the virus. Monoclonal antibodies specific to the p24 protein are 
mixed with the person's blood. Any p24 protein in the person's blood will stick to the 
monoclonal antibody and an enzyme-linked antibody to the monoclonal antibodies to p24 
causes a color change if p24 was present in the sample. 
This test is no longer used routinely in the US [2] or the EU [3] to screen blood 
donations since the objective was to reduce the risk of false negatives in the window period. 
Nucleic acid testing (NAT) is more effective for this purpose, and p24 antigen testing is no 
longer indicated if a NAT test is performed. The p24 antigen test is not useful for general 
diagnostics, as it has very low sensitivity and only works during a certain time period after 
infection before the body produces antibodies to the p24 protein 
Nucleic-acid-based tests: 
Nucleic-acid-based tests amplify and detect one or more of several target sequences 
located in specific HIV genes, such as HIV-I GAG, HIV-II GAG, HIV-env, or the HIV-
pol. Since these tests are relatively expensive, the blood is screened by first pooling some 8-
24 samples and testing these together; if the pool tests positive, each sample is retested 
individually. Although this results in a dramatic decrease in cost, the dilution of the virus in 
the pooled samples decreases the effective sensitivity of the test, lengthening the window 
period by 4 days (assuming a 20-fold dilution, ~20hr virus doubling time, detection limit 50 
copies/ml, making limit of detection 1,000 copies/ml). Since 2001, donated blood in 
the United States has been screened with nucleic-acid-based tests, shortening the window 
period between infection and detectability of disease to a median of 17 days (95% CI, 13-28 
Days, assumes pooling of samples). A different version of this test is intended for use in 
conjunction with clinical presentation and other laboratory markers of disease progress for 
the management of HIV-1-infected patients. 
In the RT-PCR test, viral RNA is extracted from the patient's plasma and is treated 
with reverse transcriptase (RT) to convert the viral RNA into cDNA. The polymerase chain 
reaction (PCR) process is then applied, using two primers unique to the virus's genome. After 
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PCR amplification is complete, the resulting DNA products are hybridized to 
specific oligonucleotides bound to the vessel wall, and is then made visible with a probe 
bound to an enzyme. The amount of virus in the sample can be quantified with sufficient 
accuracy to detect threefold change. 
In the Quantiplex bDNA or branched DNA test, plasma is centrifuged to 
concentrate the virus, which is then opened to release its RNA. Special oligonucleotides that 
bind to viral RNA and to certain oligonucleotides bound to the wall of the vessel are added. 
In this way, viral RNA is fastened to the wall. Then new oligonucleotides that bind at several 
locations to this RNA are added and other oligonucleotides that bind at several locations to 
those oligonucleotides. This is done to amplify the signal. Finally, oligonucleotides that bind 
to the last set of oligonucleotides and that are bound to an enzyme are added; the enzyme 
action causes a color reaction, which allows quantification of the viral RNA in the original 
sample. Monitoring the effects of antiretroviral therapy by serial measurements of plasma 
HIV-1 RNA with this test has been validated for patients with viral loads greater than 25,000 
copies per milliliter. 
 Other tests for HIV treatment: 
The CD4 T-cell count is not an HIV test, but rather a procedure where the number 
of CD4 T-cells in the blood is determined. 
A CD4 count does not check for the presence of HIV. It is used to monitor immune 
system function in HIV-positive people. Declining CD4 T-cell counts are considered to be a 
marker of progression of HIV infection. A normal CD4 count can range from 500 cells/mm3 
to 1000 cells/mm3. In HIV-positive people, AIDS is officially diagnosed when the count 
drops below 200 cells/μL or when certain opportunistic infections occur. This use of a CD4 
count as an AIDS criterion was introduced in 1992; the value of 200 was chosen because it 
corresponded with a greatly increased likelihood of opportunistic infection. Lower CD4 
counts in people with AIDS are indicators that prophylaxis against certain types of 
opportunistic infections should be instituted. 
Low CD4 T-cell counts are associated with a variety of conditions, including many 
viral infections, bacterial infections, parasitic infections, sepsis, tuberculosis, 
coccidioidomycosis, burns, trauma, intravenous injections of foreign proteins, malnutrition, 
over-exercising, pregnancy, normal daily variation, psychological stress, and social isolation.  
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This test is also used occasionally to estimate immune system function for people 
whose CD4 T cells are impaired for reasons other than HIV infection, which include several 
blood diseases, several genetic disorders, and the side effects of many chemotherapy drugs. 
In general, the lower the number of T cells the lower the immune system's function 
will be. Normal CD4 counts are between 500 and 1500 CD4+ T cells/microliter, and the 
counts may fluctuate in healthy people, depending on recent infection status, nutrition, 
exercise, and other factors. Women tend to have somewhat lower counts than men 
PRECAUTIONS: [5] 
Transmission-Based Precautions: 
Transmission-Based Precautions, also known as additional infection 
control precautions in health care, are the latest routine infection prevention and control 
practices applied for patients who are known or suspected to be infected or colonized with 
infectious agents, including certain epidemiologically important pathogens. The latter require 
additional control measures to effectively prevent transmission. 
Contact Precautions: 
Contact Precautions Contact Precautions are intended to prevent transmission of 
infectious agents, including epidemiologically important microorganisms, which are spread 
by direct or indirect contact with the patient or the patient‘s environment. The specific agents 
and circumstance for which Contact Precautions are indicated are found in Appendix A of the 
Guidance. The application of Contact Precautions for patients infected or colonized with 
MDROs is described in the 2006 HICPAC/CDC MDRO guideline. Contact Precautions also 
apply where the presence of excessive wound drainage, fecal incontinence, or other 
discharges from the body suggest an increased potential for extensive environmental 
contamination and risk of transmission. A single-patient room is preferred for patients who 
require Contact Precautions. When a single-patient room is not available, consultation with 
infection control personnel is recommended to assess the various risks associated with other 
patient placement options (e.g., cohorting, keeping the patient with an existing roommate). In 
multi-patient rooms, >3 feet spatial separation between beds is advised to reduce the 
opportunities for inadvertent sharing of items between the infected/colonized patient and 
other patients. Healthcare personnel caring for patients on Contact Precautions wear a gown 
and gloves for all interactions that may involve contact with the patient or potentially 
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contaminated areas in the patient‘s environment. Donning PPE upon room entry and 
discarding before exiting the patient room is done to contain pathogens, especially those that 
have been implicated in transmission through environmental contamination (e.g., VRE, C. 
difficile, noroviruses and other intestinal tract pathogens; RSV) 
Universal precautions: 
Universal precautions refers to the practice, in medicine, of avoiding contact with 
patients' bodily fluids, by means of the wearing of nonporous articles such as medical 
gloves, goggles, and face shields. The practice was introduced in 1985–88.  In 1987, the 
practice of universal precautions was adjusted by a set of rules known as body substance 
isolation. In 1996, both practices were replaced by the latest approach known as standard 
precautions (health care). Nowadays and in isolation, practice of universal precautions has 
historical significance. 
Under universal precautions all patients were considered to be possible carriers of 
blood-borne pathogens. The guideline recommended wearing gloves when collecting or 
handling blood and body fluids contaminated with blood, wearing face shields when there 
was danger of blood splashing on mucous membranes and disposing of all needles and sharp 
objects in puncture-resistant containers. 
Universal precautions were designed for doctors, nurses, patients, and health care 
support workers who were required to come into contact with patients or bodily fluids. This 
included staff and others who might not come into direct contact with patients. 
Pathogens fall into two broad categories, blood borne (carried in the body fluids) and 
airborne. 
USE: 
Universal precautions were typically practiced in any environment where workers 
were exposed to bodily fluids, such as: 
Blood 
 Semen 
 Vaginal secretions 
 Synovial fluid 
 Amniotic fluid 
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 Cerebrospinal fluid 
 Pleural fluid 
 Peritoneal fluid 
 Pericardial fluid 
Bodily fluids that did not require such precautions included: 
  Feces 
 Nasal secretions 
 Urine 
 Vomitus 
 Perspiration 
 Sputum 
 Saliva 
Universal precautions were the infection control techniques that were recommended 
following the AIDS outbreak in the 1980s. Every patient was treated as if infected and 
therefore precautions were taken to minimize risk. 
Essentially, universal precautions were good hygiene habits, such as hand washing and 
the use of gloves and other barriers, correct handling of hypodermic needles and scalpels, and 
aseptic techniques. 
PREVENTION: 
HIV PREVENTION STRATAGIES: 
Pharmaceutical strategies: 
Some commonly considered pharmaceutical interventions for the prevention of HIV include 
the use of the following: 
 microbicides for sexually transmitted diseases 
 pre-exposure prophylaxis 
 post-exposure prophylaxis 
 HIV vaccines 
 circumcision (see also Circumcision and HIV)  
 antiretroviral drugs to reduce viral load in the infected, and 
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 condoms 
Of these, the only universally medically proven method for preventing the spread of HIV 
during sexual intercourse is the correct use of condoms, and condoms are also the only 
method promoted by health authorities worldwide. For HIV positive mothers wishing to 
prevent the spread of HIV to their child during birth, antiretroviral drugs have been medically 
proven to reduce the likelihood of the spread of the infection. Scientists worldwide are 
currently researching other prevention systems.  
Increased risk of contracting HIV often correlates with infection by other diseases, 
particularly other sexually transmitted infections. Medical professionals and scientists 
recommend treatment or prevention of other infections such as herpes, hepatitis A, hepatitis 
B, hepatitis C, human papillomavirus, syphilis, gonorrhea, and tuberculosis as an indirect 
way to prevent the spread of HIV infection. Often doctors treat these conditions with 
pharmaceutical interventions.  
Social strategies 
Social strategies do not require any drug or object to be effective, but rather require 
persons to change their behavior in order to gain protection from HIV. Some social strategies 
which people consider include the following 
 sex education 
 LGBT sex education 
 needle-exchange programs 
 safe injection sites 
 safe sex 
 serosorting 
 sexual abstinence 
These strategies have widely differing levels of efficacy, social acceptance, and 
acceptance in the medical and scientific communities.  
Populations which receive HIV testing are less likely to engage in behaviors with high 
risk of contracting HIV, so HIV testing is almost always a part of any strategy to encourage 
people to change their behavior to become less likely to contract HIV. 
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TREATMENT: 
[12] 
Lopinavir/ritonavir is a fixed dose combination drug for the treatment 
of HIV infection. It combines lopinavir (not available as a single drug) with a sub-therapeutic 
dose of ritonavir (trade name Norvir) into a fixed-dose pill. 
The combination is marketed by Abbott as Kaletra (high-income countries) 
and Aluvia (low-income countries), as a component of combination therapy to treat 
HIV/AIDS. The Kaletra formulation has also been used successfully as monotherapy in some 
studies.  
As of 2006, lopinavir/ritonavir forms part of the preferred combination for first-line therapy 
recommended by the US DHHS. It is available as capsules, tablets and oral solution. 
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REVIEW OF LITERATURE 
Sameer H Lakade et al.,(2010)
[16] 
reported that Solid dispersions are used to obtain a 
homogeneous distribution of a small amount of drug in solid state. To stabilize the unstable 
drug. To dispense liquid (up to 10%) or gaseous compounds in a solid dosage. To formulate a 
fast release primary dose in a sustained released dosage form. To formulate sustained release 
regimen of soluble drugs by using poorly soluble or insoluble carriers. Polymorphs in a given 
system can be converted into isomorphs, solid solution, eutectic or molecular addition 
compounds. Many more different types of polymers are used to solve the solubility problem 
by using solid dispersion method, hence solid dispersion is a very use full method for 
Pharmaceutical point of view because of this simple and convenient reason this method is 
widely used to study various approaches & application of drug property and polymers used in 
Pharmaceutical research. 
Abu T. M. Serajuddin et al.,(1999)
 [17] 
reported that although there was a great interest in 
solid dispersion systems during the past four decades to increase dissolution rate and 
bioavailability of poorly water-soluble drugs, their commercial use has been very limited, 
primarily because of manufacturing difficulties and stability problems. Solid dispersions of 
drugs were generally produced by melt or solvent evaporation methods. The materials, which 
were usually semisolid and waxy in nature, were hardened by cooling to very low 
temperatures. They were then pulverized, sieved, mixed with relatively large amounts of 
excipients, and encapsulated into hard Gelatin capsules or compressed into tablets. These 
operations were difficult to scale up for the manufacture of dosage forms. The situation has, 
however, been changing in recent years because of the availability of surface-active and self-
emulsifying carriers and the development of technologies to encapsulate solid dispersions 
directly into hard gelatin capsules as melts. Solid plugs are formed inside the capsules when 
the melts are cooled to room temperature. Because of surface activity of carriers used, 
complete dissolution of drug from such solid dispersions can be obtained without the need for 
pulverization, sieving, mixing with excipients, etc. Equipment is available for large-scale 
manufacturing of such capsules. Some practical limitations of dosage form development 
might be the inadequate solubility of drugs in carriers and the instability of drugs and carriers 
at elevated temperatures necessary to manufacture capsules. 
 
Ali Nokhodchi et al.,(2007)
 [18] 
worked on solid dispersions of chlordiazepoxide techniques 
to improve its dissolution rate. To this end, three techniques namely, two solvent methods 
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and co-grinding technique were used. Solid dispersions of chlordiazepoxide in 
polyvinylpyrrolidone (PVP), Eudragit E100, Mannitol and Sorbitol with two different ratios 
of drug to carrier (5:5 and 1:9) were prepared. These solid dispersions were evaluated using 
dissolution tester to monitor dissolution behavior and Fourier-transform infrared 
spectroscopy to investigate interaction between the drug and carriers in solid dispersion 
samples. Solid dispersion ofchlordiazepoxide with all three carriers (PVP, mannitol and 
eudragit E) prepared by solvent method showed Considerable increase in the dissolution rate 
of chlordiazepoxide in comparison with physical mixture and pure drug at different pH 
values. According to the results of this investigation co grinding technique yields solid 
dispersions with a less improved dissolution rate than doe’s the solvent deposition technique. 
Infrared studies showed no interaction between chlordiazepoxide and carriers in solid 
dispersions in solid state. 
 
Dehghan et al.,(2010) 
[19] 
worked on the solubility and dissolution of Glipizide in water by 
solid dispersion. The solid dispersion of glipizide was prepared using water soluble carriers 
such as polyethylene glycol (PEG) andmannitol by fusion method and PVP K 30 by solvent 
evaporation method in an attempt to increase the solubility and dissolution rate of Glipizide- 
a practically insoluble drug in water. IR spectroscopy and in-vitro dissolution studies were 
used to characterize the solid dispersion. FTIR studies show no chemical interaction between 
Glipizide and PEG6000, mannitol and PVP K 30. The solid dispersion prepared in this study 
was found to have higher dissolution rate and solubility compared to plain drug and physical 
mixture of drug and carriers. It was found that the optimum weight ratio 1.5 for PEG-6000 
shows higher solubility and dissolution rate. Finally it was concluded that PEG-6000 shows 
greater dissolution enhancing capacity than mannitol and PVP K 30. 
 
Mohamed Hassan et al.,(2006) 
[20] 
reported that Meloxicam is a poorly water soluble non-
steroidal anti-inflammatory drug and antipyretic agent. The aim of the present work was to 
investigate the effect of different types of carriers on in vitro dissolution of meloxicam. 
Meloxicam solid dispersions were prepared by physical mixing, co-grinding and solvent 
evaporation methods with polyethylene glycol (PEG) 6000.The effect of solubilization by 
sodium lauryl sulphate (SLS) was also studied. The dissolution was determined by USP 
XXVII Apparatus I, using phosphate buffer with a pH of 7.4 as the dissolution medium. The 
maximum in vitro dissolution of meloxicam, i.e. 97.45% in 60 min,was observed for solid 
dispersions containing meloxicam (150 mg), PEG 6000 (350 mg) and SLS (75 mg) prepared 
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by solvent evaporation method containing a sum of 3 g of Lactose and MCC (4:1) as 
additives. The general trend indicated that there was an increase in dissolution rate for solid 
dispersions containing the solubilizer SLS. The best-fit model indicating the mechanism of 
dissolution from the formulation showing the highest release for was found to be Higuchi 
matrix release (r=0.9774, b=13.042, a=2.4798). Infra-red spectroscopy (IR) indicated that 
meloxicam in solid dispersions showed physical entrapment. The increased in dissolution rate 
of meloxicam by solid dispersion technique may be due to increase wettability and 
hydrophilic nature of carrier. 
 
Kothawade et al.,(2010) 
[21] 
reported that Solubility is an important physicochemical factor 
affecting absorption of drug and its therapeutic effectiveness. Consequences of poor aqueous 
solubility would lead to failure in formulation development. The poor solubility of drug 
substances in water and their low dissolution rate in aqueous G.I.T fluid often leads to 
insufficient bioavailability. In the present investigation, an attempt was made to improve the 
solubility and dissolution rate of a poorly soluble drug, Telmisartan. Solid dispersions were 
prepared using polyvinyl pyrrolidone (PVP), Polyethyleneglycol-1500 (PEG-1500) and 
Polyethylene glycol-4000(PEG-4000) to increase its aqueous solubility. Telmisartan solid 
dispersions were prepared in 1:1, 1:2 and 1:4 ratios of the drug to polymer ratio (by weight) 
using solvent evaporation method. The formulations were characterized for solubility 
parameters, drug content studies, drug release studies and drug-polymer interactions by using 
FTIR spectrum. Formulation containing 1:2 ratio of drug: PEG-4000 showed the best release 
with a cumulative release of 99.49% as compared to 35.82 % for the pure drug. The 
interaction studies showed no interaction between the drug and polymer. It was concluded 
that PEG-4000 as a carrier can be very well 
Utilized to improve the solubility of poorly soluble drugs. 
 
Ganesh Chaulang et al.,(2009) 
[22] 
reported that enhancement of the dissolution rate of 
furosemide using solid dispersion (SD) withcrospovidone (CPV) by using kneading 
technique. 1:1 (w/w) and 1:2 (w/w) solid dispersions were prepared by kneading method 
using solvent water and ethanol in 1:1 ratio. Dissolution studies using the USP paddle method 
were performed for solid dispersions of furosemide at 37 ± 0.5oC and 50 rpm in simulated 
gastric fluid (SGF) of pH 1.2. Fourier transformer infrared (FTIR) spectroscopy, differential 
scanning calorimetric (DSC), and x-ray diffractometry (XRD) were performed to identify the 
physicochemical interaction between drug and carrier, hence its effect on dissolution. Tablets 
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were formulated containing solid dispersion products and compared with commercial 
products. IR spectroscopy, XRD, and DSC showed change in the crystal structure towards 
amorphous one of furosemide (FRMD). Dissolution of furosemide improved significantly in 
solid dispersion the 1:2 solid dispersion indicated increase in dissolution 5.11 fold. Tablets 
containing solid dispersion exhibited better dissolution profile than commercial tablets. Thus, 
the solid dispersion technique can be successfully used for improvement of dissolution of 
furosemide. 
 
Apparao et al.,(2010) 
[23] 
reported that Aceclofenac is a novel non-steroidal anti-
inflammatory drug (NSAID) having anti-inflammatory and analgesic properties, and is 
widely used in the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing 
spondylitis. One of the major problems with this drug is its low solubility in biological fluids, 
which results into poor bioavailability after oral administration. Therefore, solid dispersions 
(SDs) of Aceclofenac were prepared using lactose, mannitol and urea to increase its aqueous 
solubility. Aceclofenac SDs was prepared in 9:1, 7:3 and 4:1 ratios of the drug to polymer (by 
weight).In vitro release profiles of all SDs (F-1 to F-9) were comparatively evaluated and 
also studied against pure Aceclofenac. Faster dissolution was exhibited by solid dispersion 
containing 9:1 ratio of drug: lactose. The increase in dissolution rate of the drug may be due 
to increase in wettability, hydrophilic nature of the carrier and due to reduction in drug 
crystallinity.The prepared solid dispersion was subjected for % practical yield, drug content 
and infrared (IR) spectroscopic studies. Absence of significant drug-carrier interaction was 
confirmed by infrared spectroscopic (IR) data. 
 
Muralidhar et al.,(2011) 
[24] 
worked on Etoricoxib, a non-steroidal anti-inflammatory drug, 
is used to Osteoarthritis, Rheumatoid arthritis and Acute Gouty arthritis. Etoricoxib is 
practically insoluble in water; hence present study was carried out to enhance dissolution 
properties of Etoricoxib through the preparation of Solid Dispersions using PEG 6000 as 
carrier at various proportions by using different techniques like Physical mixtures, Kneading 
Method and Solvent Evaporation Method. The drug release profile was studied in 0.1N HCl 
containing 1 % SLS. U.V. Spectrophotometric method was selected for assay as well as in-
vitro dissolution studies at 234nm.All the solid dispersions exhibited superior dissolution than 
pure drug. The drug dissolution studies followed first order kinetics. Solvent evaporation 
method was found to be superior to other methods. 
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Guptha et al.,(2011) 
[25] 
reported that Ibuprofen is (NSAID) non‐steroidal anti‐inflammatory 
drug and used as analgesic & anti‐inflammatory drug. It can be also used in the treatment of 
rheumatoid arthritis, osteoarthritis, and primary dysmenorrhea. Ibuprofen is absorbed rapidly, 
bound avidly to protein, but it has low aqueous solubility so, it also lowers the dissolution 
profile of drug. To overcome this problem, various techniques are used, like solid dispersion, 
complexation, co‐solvency, hydro trophy, Nano technology approach. In this study, the 
dissolution rate of poorly soluble drug Ibuprofen was increased by preparing solid dispersion 
with urea in ratio of (1:1), (1:3) & (1:5) by using melt dispersion method & solvent 
evaporation method. The rate of dissolution of Ibuprofen was increased with the proportion 
of (1:5) when compared to the other formulations. 
 
Tejas Patel et al.,(2010) 
[26] 
worked on Fenofibrate is a lipid lowering drug used in the 
treatment of hyperlipidemia, which is not soluble in water and lower absorption in gastric 
fluid. In order to improve the solubility and oral absorption of the drug in gastric fluid and to 
enhance its dissolution rate solid dispersions and Lyophilization of dispersion is designed and 
evaluated. Solid dispersions of Fenofibrate were prepared using PEG 6000, Poloxamer 407 
and a mixture of PEG 6000 and Poloxamer 407(1:1 mixture). The effect of melt and solvent 
methods of preparation of solid dispersion on dissolution behavior was also investigated. 
Dissolution studies indicated a significant increase in dissolution of Fenofi-brate when 
dispersed in PEG6000 and Poloxamer 407. Physical mixtures containing PEG and Poloxamer 
407 also showed improved dissolution of Fenofibrate as compared with that of pure drug, 
indicating the solubilizing effect of PEG6000 and Poloxamer 407. Solid dispersions 
containing Fenofibrate /Poloxamer 407, 1: 8, showed a 14-fold increase in dissolution after 
60 min (D60) and another dispersion containing Fenofibrate /PEG 6000, 1:10, showed an 8-
fold increase in the 0.1 N HCl systems. The dispersion containing six parts of the PEG 6000: 
Poloxamer 407 mixture (PEG 4000/PEG 6000, 1:1 mixture) showed a 12-fold increase in 
D60 as compared with pure drug. When multi-carrier solid dispersion containing six parts of 
mixture was prepared by the solvent method, the D60 value was about 2-fold that of the same 
dispersion prepared by the melt method. The dissolution of lyophilized solid dispersions 
further increased the dissolution of Fenofibrate significantly. 
 
Arun Prasad et al.,(2010) 
[27] 
reported that the study was aimed to formulate solid dispersion 
tablet of Terbinafine Hydrochloride by using carrier’s polyethylene glycol 6000 (by melting 
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method) and polyvinyl pyrrolidone K 30 (by solvent method) in the drug carrier ratio of 1:1, 
1:2 and 1:3. The prepared solid dispersions were characterized for their drug content, thermal 
studies, infrared spectral studies, differential scanning calorimetric studies, aqueous solubility 
studies and in-vitro release studies. From the results, it was clear that solid dispersion 
formulation showed improved 
Dissolution rate than pure drug and physical mixture. The solid dispersion showing better 
release profile was chosen to formulate into  tablet dosage form of weight 
600mg.Thetabletscompressed were evaluated for its physical parameters like thickness, 
hardness, weight Variation, friability, drug content and disintegration tests. The dissolution 
profile of formulated tablet was compared with the marketed product and the formulated 
tablet showed better release profile than the marketed product. 
 
Dhirendra et al.,(2009) 
[28] 
reported that Solid dispersions have attracted considerable 
interest as an efficient means of improving the dissolution rate and hence the bioavailability 
of a range of hydrophobic drugs. This article reviews the various preparation techniques for 
solid dispersion and compiles some of the recent technology transfers. The different types of 
solid dispersions based on the molecular arrangement have been highlighted.  Some of the 
practical aspects to be considered for the preparation of solid dispersions, such as selection of 
carrier and methods of physicochemical characterization, along with an insight into the 
molecular arrangement of drugs in solid dispersions are also discussed. Finally, an in-depth 
rationale for limited commercialization of solid dispersions and recent revival has been 
considered. 
Klein Cheri Enders et al.,(2010) 
[29] 
reported that Lopinavir, an HIV protease inhibitor, is co 
-formulated with ritonavir to enhance the bioavailability and pharmacokinetics of lopinavir. 
The original solid oral formulation of lopinavir/ritonavir, a soft-gelatin capsule (SGC), 
requires refrigerated storage, is taken as 6 capsules daily at the recommended adult dose, and 
is administered with food to maximize the bioavailability of lopinavir. Melt extrusion 
technology was used to produce a tablet formulation reducing the number of dosage units 
administered per day and simplifying storage requirements. Three studies assessed the 
bioavailability of tablet doses of lopinavir/ritonavir at 800/200 mg or 400/100 mg under 
different meal conditions compared with equal doses of the SGC after a moderate-fat meal. 
The tablet was bioequivalent to the SGC after a moderate-fat meal with respect to lopinavir 
and ritonavir areas under the concentration-time curve. Compared with the SGC formulation, 
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the tablet formulation resulted in more consistent lopinavir and ritonavir exposures within 
and across studies and across meal conditions. The diminished food effect and decreased 
variability of the tablet are likely to result in more consistent lopinavir and ritonavir 
exposures, minimizing the likelihood of extreme high or low values compared with the SGC. 
Rahul hastel et al.,(2009) 
[30] 
reported that over the years, a variety of solubilization 
techniques have been studied and widely used, by many estimates up to 40 per cent of new 
chemical entities discovered by the pharmaceutical industry today are poorly soluble or 
lipophilic compounds. The solubility issues complicating the delivery of these new drugs also 
affect the delivery of many existing drugs. The various techniques are available for 
enhancement of solubility. Solid dispersion is one of the most promising approaches for 
solubility enhancement. The term solid dispersion refers to a group of solid products 
consisting of at least two different components, generally a hydrophilic matrix and a 
hydrophobic drug. The matrix can be either crystalline or amorphous. 
Shrotriya et al.,(2007) 
[31] 
reported that Embelin 2, 5-dihydroxy-3-undecyl-1, 4-
benzoquinone, a chemical component available in dried fruits of Embeliaribesburm F. shows 
its anthelmintic activity against tapeworms. Embelin is practically insoluble in water. There is 
a need for solubility enhancement of Embelin in order to enhance its absorption through 
intestine. The study was aimed to formulate solid dispersions of Embelin by using various 
carriers (PVP, PVP- K 30, PEG 6000 & PEG 4000) in three different ratios (1:0.5, 1:1 and 
1:1.5) using solvent evaporation technique. The prepared solid dispersions were characterized 
using infrared spectral studies, differential scanning calorimetric studies, aqueous solubility 
studies, drug content and in-vitro release profile. From FT-IR, XRD, and DSC studies no 
interaction between Embelin and carrier was observed. Solid dispersion of Embelin with PVP 
in 1:1 ratio showed maximum enhancement in the solubility of Embelin as well as % drug 
release after 2 hrs. in phosphate buffer pH 7.4. Thus, the solid dispersion technique can be 
successfully used for improvement of solubility and dissolution profile of Embelin. 
Successful attempt was made to enhance the solubility of Embelin using solid dispersion 
technique. Keywords: : Solid dispersion, Embelin, Solvent Evaporation, Dissolution 
enhancement. 
Shinde et al.,(2010) 
[32] 
reported that the solubility behavior of drug is one of most 
challenging aspect in formulation development. Thus a greater understanding of dissolution 
& absorption behavior of drug with low aqueous solubility is required to successfully 
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formulate them into more soluble and hence bioavailable drug product. Therefore different 
approaches are being explored to enhance the solubility of poorly water soluble drugs, one of 
such approach is using solid dispersion by solvent evaporation method. In this study, we are 
trying to increase the solubility of Aceclofenac, poorly water soluble drug with low 
bioavailability. Objective of this work is to improve the solubility and dissolution rate of 
poorly water soluble Aceclofenac by solid dispersion method followed by solvent 
evaporation method. And to compare effectiveness of hydrophilic polymer PVP-k30, HPMC 
E-5, using porous carrier Aerosil 200. , resultant complexes were evaluated for drug content, 
infrared spectroscopy, and XRD and dissolution study.  The present study successfully 
utilized the solvent evaporation method for preparation of stable, amorphous solid dispersions 
of Aceclofenac by encapsulation with hydrophilic carrier with adsorbents agent (Batch 4, 
1:1:2) drug: PVPK30: aerosil, showed maximum release in phosphate buffer pH 6.8 The 
present study demonstrates high potential of solvent evaporation method for obtaining large 
surface area and amorphicity of drug using hydrophilic carrier   
Sheikh Tasnim Jahan et al.,(2008) 
[33] 
reported that the objective of present work is to 
investigate the enhancement of dissolution profile for oral delivery of Fexofenadine 
Hydrochloride (FH) through solid dispersion (SD) technique by the method of solvent 
evaporation. The SD was prepared by using ethanol as a solvent. Tablets were formulated 
containing solid dispersion of FH and compared with tablets of same formula without solid 
dispersion of FH. The using of ethanol to prepare solid dispersion found a significant effect 
on the dissolution of FH. Dissolution studies using the USP-33 paddle method were 
performed for tablets formulated with and without solid dispersions of FH. Dissolution of FH 
improved significantly in tablets formulated with SD (85% in 10 minutes) exhibited better 
dissolution profile than tablets formulated without SD. Infrared (IR) spectroscopy was also 
performed to identify the physicochemical interaction between drug and solvent, hence its 
effect on dissolution.   
Rakesh et al.,(2010) 
[34] 
reported that the Solid dispersions traditionally have been used as 
effective methods to improve the dissolution properties and bioavailability of poorly water-
soluble drugs. The aim of the present study was to improve the solubility and dissolution rate 
of a poorly water-soluble drug, furosemide, by a solid dispersion technique. Solid dispersions 
were prepared using polyethylene glycol 6000 (PEG 6000) and polyvinylpyrrolidone K30 
(PVP K30) in different drug-to-carrier ratios. Dispersions with PEG 6000 were prepared by 
fusion-cooling and solvent evaporation, while dispersions containing PVP K30 were prepared 
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by solvent evaporation technique. These new formulations were characterized in the liquid 
state by phase solubility studies and in the solid state by differential scanning calorimetry, 
powder X-ray diffraction, and FTIR spectroscopy. The aqueous solubility of furosemide was 
favored by the presence of both polymers. Solid state characterizations indicated that 
furosemide was present as an amorphous material and entrapped in polymer matrix. In 
contrast to the very slow dissolution rate of pure furosemide, the dispersion of the drug in the 
polymers considerably enhanced the dissolution rate. Solid dispersion prepared with PEG 
showed the most improvement in wettability and dissolution rate of furosemide. Even 
physical mixtures of furosemide prepared with both polymers also showed better dissolution 
profiles as compared with that of pure furosemide. Tablets prepared using solid dispersions 
showed significant improvement in the release profile of furosemide as compared with 
conventional tablets prepared using furosemide without PEG or PVP. 
Sruti Ranjan Mishra et al.,(2009) 
[35] 
reported that the Pioglitazone hydrochloride is a novel 
antidiabetic drug in thiazolidinediones group and it improves insulin sensitivity in insulin 
resistant patients. One of the major problems with this drug is its low solubility in biological 
fluids, which results into poor bioavailability after oral administration. The present study is 
an attempt to enhance the dissolution rate of pioglitazone HCl by solvent evaporation and 
physical mixture techniques using pioglitazone HCl and PEG 6000 as carrier in the ratios of 
1:1, 1:2 and 1:3 respectively. The drug carrier interaction study was carried out by Fourier 
Transform Infrared Spectroscopy (FTIR). The prepared solid dispersions were characterized 
for percentage yield, bulk density, tapped density, Carr’s Index, Hausner’s ratio, angle of 
repose, drug content, drug dissolution and stability study. The FTIR study suggesting no 
interaction between drug and carrier of solid dispersion. The solvent evaporation and physical 
mixture techniques were found to be efficient method to obtained good yield solid 
dispersions with good flow properties. The drug content was found in the ranges of 75.6±0.34 
to 85.2±0.22 %. Dissolution study revealed that there is marked enhancement in the 
dissolution rate of pioglitazone from all the solid dispersions when compared to pure 
pioglitazone itself. From the in vitro drug release profile, it can be seen that formulation F3 
(1:3 ratio of drug: PEG 6000, prepared by solvent evaporation) shows higher dissolution rate 
compared with other formulations. All pioglitazone solid dispersions were found to be stable 
in various storage temperatures. The solvent evaporation is suitable method for development 
of solid dispersion of pioglitazone HCl. 
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Evangelos Karavas et al.,(2010) 
[36] 
reported that the Polyvinylpyrrolidone (PVP) and poly 
(ethylene glycol) (PEG) solid dispersions with Felodipine or Hesperetin having up to 20 wt.% 
drug were prepared using solvent evaporation method. Solid dispersions in comparison with 
their physical mixtures were studied using differential scanning calorimetry (DSC), wide-
angle X-ray diffraction (WAXD), scanning electron microscopy (SEM) and hot stage 
polarizing light microscopy (HSM).PVP formulations with low drug load proved to be 
amorphous, since no crystalline Felodipine or Hesperetin drugs were detected using DSC and 
WAXD. Low and fast heating rates were applied for DSC study, to prevent changes in the 
samples caused during heating. Similarity between results of WAXD and DSC was also 
found in the case of physical mixtures, where the drug was in the crystalline state. However, 
though speciﬁc tests showed the high sensitivity of the DSC technique, it was difﬁcult to 
arrive to reliable results for PEG solid dispersions or physical mixtures with low drug content 
by DSC, even by high heating rates. Crystalline drug could not be detected by DSC, leading 
to erroneous conclusions about the physical state of the drug, in contrast to WAXD. On the 
other hand, HSM proved the presence of small drug particles in the solid dispersions with 
PEG and the dissolution of the drug in the melt of PEG on heating. In such systems, in which 
a polymer with low melting point is used as drug carrier, DSC is inappropriate technique and 
must be used always in combination with HSM. The coupling of WAXD with thermal 
analysis, allowed complete physicochemical characterization and better understanding which 
is essential for a ﬁrst prediction of dissolution characteristics of such formulations. 
Arora et al., (2007) 
[37] 
reported that the Cefuroxime Axetil (Poorly water soluble drug), 
when prepared as solid dispersion showed improved solubility and dissolution. Therefore, the 
main purpose of this investigation was to increase the solubility and dissolution rate of 
Cefuroxime Axetil by the preparation of its solid dispersion with urea, using the solvent 
evaporation method. Physical mixtures and solid dispersions of Cefuroxime Axetil were 
prepared by using urea as a water-soluble carrier in various proportions (1:1, 1:2, 1:3, 1:4, 
1:5, 1:6, and 1:7 by weight), by employing the solvent evaporation method. The drug release 
profile was studied and it was found that the dissolution rate and the dissolution parameters 
of the drug from the physical mixture as well as solid dispersion were higher than those of the 
intact drug. The Fourier Transform Infrared (FTIR) spectra revealed no chemical 
incompatibility between the drug and urea. Drug-polymer interactions were investigated 
using differential scanning calorimetry (DSC) 
Aim and objective 
 
Department of Pharmaceutics, Nandha College of Pharmacy, Erode. Page 46 
 
Aim and Objective 
The main aim and objective of this project is to improve the dissolution rate of 
Lopinavir by improving its solubility in dissolution medium by Solid Dispersion Technique. 
Poorly water soluble drugs require high doses in-order to reach therapeutic plasma 
levels after oral administration. Improvement in-extent and rate of dissolution is highly 
desirable for such compound as this can lead to an increased and more re-producible oral bio-
availability and sub-sequent to clinical relevant dose reduction to more reliable therapy. 
Now-a-days, pharmaceutical techniques provide many approaches to enhance the 
dissolution rate of poorly water soluble drugs. Solid dispersion technique can be used to 
enhance the solubility dissolution rate and absorption of several insoluble drugs. Various 
hydrophilic carries like, PEG, PVP, HPMC, SLS, Gums have been investigated for 
improvement of dissolution characteristics, bio-availability for poorly aqueous soluble drugs. 
Lopinavir is an anti-retroviral drug of protease inhibitor. According to 
biopharmaceutical classification system (B.C.S)-II. It is a poorly water soluble drug, having 
bio-availability of less than 5% and high permeability so it was chosen as a model for this 
research work. 
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Plan of Work 
 Preparation of Solid dispersions using Poly Vinyl Pyrrolidine (PVP), Mannitol, 
Sodium Lauryl Sulphate (SLS) and Urea as carriers to increase its aqueous solubility 
in the ratios 1:2 and 1:4 of the drug to carrier (by weight) using solvent evaporation 
method. 
 FT-IR studies 
 Characterization of formulations for: 
 Pre-formulation studies 
 Bulk density 
 Tapped density 
 Compressibility index 
 Angle of repose 
 Drug content studies 
 Formulation of conventional tablets of Lopinavir from solid dispersed powder 
 Evaluation tests 
 Hardness test 
 Friability test 
 Weight variation test 
 Disintegration test 
 Drug release studies 
 Stability test 
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DRUG PROFILE 
[6, 7, 8] 
Drug: LOPINAVIR 
IUPAC Name: 
                [(2, 6- dimethylphenoxy) acetyl] amino]-3-hydroxytetrahydro-_-(1-methylethyl)-2-oxo-
1-(2H)-pyrimidineacetamide hydroxy-5-phenyl-1-pyrimidineacetamide. 
 
Structure: 
 
 
 
 
 
 
 
 
 
 Molecular Formula: 
C37H48N4O5 
Molecular weight: 
628.8g/mol 
Melting point: 
124-127°C 
Description: 
            White powder. 
Solubility: 
Freely soluble in methanol and dichloromethane, iso- propanol, insoluble in water 
 
Stability/Storage: 
Stable at 15°C to 30°C, should be kept in a tightly closed container, and protected 
from light. 
Dosage form: 
Lopinavir 200mg, 100mg (tablets), oral solution (80mg). 
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Dose: 
400mg/day orally. 
Mechanism of action: 
Lopinavir is an antiretroviral of the protease inhibitor class. Inhibiting HIV-1 protease 
(Responsible for protein cleavage), results in selectively inhibiting the cleavage of HIV gag 
and Gag-pol polyproteins, thereby preventing viral maturation. This subsequently results in 
noninfectious, immature viral particles. 
Pharmacodynamics /kinetics: 
Bioavailability: <5% 
Protein binding: 98-99% 
Metabolism: Hepatic CYP3A 
Plasma half-life: 5-6 hrs. 
Time to peak: 4 hours following multiple doses of 400 mg of lopinavir 
                         For 3 to 4 weeks 
Peak plasma concentration: 
Lopinavir: 9.6± 4.4 micrograms per mL following multiple doses of 
                    400 mg of Lopinavir for 3 to 4 weeks. 
Excretion: Renal 10.4% and Feacal 82.6%. 
Adverse effects: 
The most common side effects associated with Lopinavir/ritonavir include: diarrhoea, 
Nausea, stomach pain, feeling weak, vomiting, headache, and upset stomach. Rare side 
effects include Pancreatitis, yellowing of the skin or eyes (jaundice), Hypersensitivity 
Reaction (unusual Skin rash, peeling of the skin, hives, swelling of the face or tongue, 
difficulty breathing), Sensation of abnormal heartbeats, Hemophilia, Diabetes or 
Hyperglycemia, fat redistribution or Accumulation, Increases in cholesterol and triglycerides. 
Applications: 
Lopinavir is an antiretroviral of the protease inhibitor class-II. It is marketed by 
Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component 
of combination therapy to treat HIV/AIDS. 
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 Polymer Profiles[9]  
Poly Vinyl Pyrrolidone (PVP): 
PVP is a water soluble polymer made from the monomer N- Vinyl pyrrolidone. It is 
represented by the formula (C6H9NO) nPVP is soluble in water and other polar solvents. In 
water it has the useful property of Newtonian viscosity.  
Description: White to tan powder; supplied in two molecular weight forms; the molecular 
weight value is an average molecular weight for the two forms. 
Structure: 
 
Functional Uses: Clarifying agent, stabilizer, bodying agent, tableting adjunct, dispersing 
agent. 
Identification: 
Solubility:Soluble in water, in ethanol and in chloroform; insoluble in ether. 
PH:3.0 - 7.0 (5% sol). 
Precipitate formation:To 5 ml of a 1 in 50 solution of the sample add 5 ml of dilute 
hydrochloric acid TS, 5 ml of water and 2 ml of 1 in 10 solution of potassium dichromate. A 
yellow precipitate forms. 
Add 5 ml of a 1 in 50 solution of the sample to 75 mg of cobalt nitrate and 0.3 g of ammonium 
thiocyanate dissolved in 2 ml of water, mix and acidify with dilute hydrochloric acid TS. A 
pale blue precipitate forms. 
To 5 ml of a 1 in 50 solution of the sample add 1 ml of 25% hydrochloric acid and 5 ml of 5% 
barium chloride solution and 1 ml of 5% phosphomolybdotungstic acid solution. A 
voluminous white precipitate is formed which becomes gradually blue on standing in daylight. 
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(Note: The blue coloration on exposure to light distinguish polyvinylpyrrolidone from 
polyethylene oxide adducts which give similar precipitates with the same reagents but which 
retain their white colour in light). 
Tests: 
Water:Not more than 5% (Karl Fischer Method) 
Relative Viscosity:Between 1.188 and 1.325 for lower molecular weight product, and between 
3.225 and 5.662 for higher molecular weight product. 
Total ash: Not more than 0.02%. 
Aldehyde:Not more than 0.2% (as acetaldehyde). 
Monomer content:  Not more than 1% (as vinylpyrrolidone). 
Hydrazine:  Not more than 1 mg/kg. 
Lead: Not more than 2 mg/kg. 
Sodium Lauryl Sulphate (SLS): 
Description: 
A white or pale yellow powder or crystals  
It is a mixture of sodium alkyl sulphates consisting mainly of sodium dodecyl sulphate,  
CH3 (CH2)10CH2OSO3Na. 
SLS contains not less than 85% of sodium alkyl sulphates calculated as C12H25NaO4S. 
Structure: 
    
Identification: 
• A 1% w/v solution, when shaken, produces plenty of foam. 
• Mix 0.1ml of a 1% w/v solution with 0.1ml of a 0.1% w/v solution of methylene blue 
and 2ml of 1M H2SO4, add 2ml of dichloromethane and shake; the dichloromethane is 
intensely blue. 
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Tests: 
Alkalinity:Dissolve 1.0g in 100ml of CO2 free water and add 0.1ml of phenol red solution. 
Not more than 0.5 ml of 0.1M HCl is required to change the colour of solution.  
Non-esterified Alcohols: Not more than 4% determined by yellowing method. 
NaCl and Sodium Sulphate: Not more than a total of 8%. 
Storage: Store protected from moisture. 
Urea: 
Urea is the diamide of carbonic acid. Urea contains not less than 99% and not more than 
101% of NH2CONH2, calculated on the dried basis. 
Description: A white, crystalline powder or transparent crystals, odorless or almost odorless 
but may graphically develop a slight odour of ammonia upon long standing; slightly 
hygroscopic. 
 
Structure: 
 
 
Identification: 
Test A may be omitted if tests B & C are carried out. Tests B & C may be omitted if test A is 
carried out. 
A) Determine by infrared absorption spectrophotometry compare the spectrum it that of 
obtained with urea RS or with the reference spectrum of urea. 
B) Heat 0.5g in a test tube, it liquefies and ammonia is evolved which is recognized by 
its characteristic odour. Heat further until the liquid is turbid, cool and dissolve in 
10ml of water. Add 1ml of a 10% w/v solution of NaOH and 0.05ml of copper 
sulphate solution; a reddish violet colour is produced. 
C) Dissolve 0.1g in 1ml of water and add 1ml of nitric acid, a white crystalline 
precipitate is produced. 
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Tests: 
Appearance of solution: Solution A is clear and colorless. 
Alkalinity: To 10ml of a 5% w/v solution (sol A) adds 0.1ml of methyl red solution and 0.4ml 
of 0.01M HCl, the resulting solution is red to orange. 
Bi-uret: Not more than 0.1%, determined by the yellowing method. 
Ethanol-insoluble matter: Not more than 0.04% determined by the yellowing method. 
Heavy Metals: Dissolve 1g in 20ml of water and 0.1M HCl. The solution complies with the 
limit test for heavy metals- Method A(20ppm). 
Sulphonated ash: Not more than 0.1%. 
Loss on Drying:  Not more than 1% determined on 1.0g by drying in an oven at 105˚ for 1hr. 
Storage: Store protected from moisture. 
Mannitol: 
Description: Mannitol is a white, crystalline organic compound with the formula 
(C6H8(OH)6). This polyol is used as an osmotic diuretic agent and a weak renal vasodilator. It 
was originally isolated from the secretions of the flowering ash, called manna after their 
resemblance to the Biblical food, and is also referred to as mannite and manna sugar. In 
plants; it is used to induce osmotic stress. 
Structure: 
 
 
Identification tests: 
Appearance: white crystalline powder 
Solubility: water soluble 
Melting point:1670c 
Half-life: 100min 
Bio availability: 7 % 
Stability: stable combustible incompatible with strong oxidizing agents. 
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Materials  
S. No Chemical name Supplier 
1 Lopinavir M.S.N chemicals, Hyderabad 
2 PVP National chemicals, Vadodara 
3 SLS NICE chemicals, pvt.ltd, Cochin 
4 Mannitol HI media laboratories, Mumbai 
5 Urea Loba chemie, Mumbai 
6 Potassium.di.hydrogen phosphate Qualigens fine chemicals, Mumbai 
7 Sodium hydroxide Loba chemie, Mumbai 
8 Mg. Stearate Sd. Fine chemicals, Mumbai 
9 Talc Sd. Fine chemicals, Mumbai 
 
Equipment 
S. 
No 
Name of the equipment Supplier 
1 Pippetes,Beakers Borosil 
2 Hot air oven Sunbim manfacture,pvt.ltd 
3 UV-spectrophotometer Shimadzu 
4 Dissolution apparatus Electro lab 
5 Friability apparatus The Asian scientific insts.co 
6 pH meter  Elico 
7 Disintegration apparatus Shreeji pharmaceuticals pvt.ltd 
8 Tablet punching apparatus Cadmach machinery Pvt.ltd 
9 FT –IR apparatus Shimadzu 
10 Hardness tester The Asian scientific insts.co 
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Preparation of solid dispersions 
 Solvent evaporation method:  
Solid dispersions of Lopinavir were prepared by solvent evaporation technique. Required 
quantities of Lopinavir, Urea, SLS, PVP and Mannitol were weighed accurately to get drug: 
polymer ratio of 1:2, 1:4. Drug and polymer were individually dissolved in a suitable solvent to 
get a homogenous solution. Now the drug solution was added to polymer solution with 
continuous stirring to form a molecular dispersion of drug and polymer.  Slowly the solvent was 
evaporated to get a solid dispersion.  
TABLE -2  
S. No COMPOSTION RATIO CODE 
1 LOPINAVIR + PVP 1:2 F1 
2 LOPINAVIR +SLS 1:2 F2 
3 LOPINAVIR +MANNITOL 1:2 F3 
4 LOPINAVIR +UREA 1:2 F4 
5 LOPINAVIR + PVP 1:4 F5 
6 LOPINAVIR + SLS 1:4 F6 
7 LOPINAVIR + MANNITOL 1:4 F7 
8 LOPINAVIR + UREA 1:4 F8 
 
FT-IR STUDIES: 
The FT-IR analysis was conducted for the analysis of drug polymer interaction and stability 
of the drug during solid dispersion processthe FT-IR spectrum of pure Lopinavir, PVP, SLS, 
UREA, and Mannitol. The physical mixture was recorded.  
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Preformulation studies: 
The following parameters are determined for solid dispersed Lopinavir. 
1. Bulk Density: 
 Bulk density is defined as a mass of powder divided by the bulk volume. Weigh 15gm 
of Solid dispersed Lopinavir powder taken into a 100 ml measuring cylinder of note the 
volume occupied by the powder as bulk volume. The bulk density was calculated in g/cm2 by 
the following formula 
, 
2. Tapped Density: 
 The above powder sample was tapped gently as surface till the powder occupies 
maximum volume and notes the volume as tapped volume. The mechanical tapping of 
cylinder was carried out manually 500 times. The tapped density was calculated in g/cm2 by 
the following formula. 
 
3. Angle of Repose: 
 The frictional forces in a loose powder can be measured by the angle of repose θ. This 
is the maximum angle possible between the surface of a pile of powder and the horizontal 
plane. 
A funnel is fixed at a particular height ‘h’ on a burette stand. A white paper is placed bellow 
the funnel. The powder sample is passed slowly through the funnel until it forms a pile 
further addition of drug stopped as soon as the drug pile touches the tube of the funnel. Circle 
of the pile of drug is drawn without disturbing the pile of radius of the pile is noted. Angle of 
repose is calculated from the following formula: 
Tanθ=h/r 
Θ=angle of repose degrees,   h=height of pile, r=radius of the pile in cm 
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4. Carr’s compressibility index: 
The same tapping method was used to determine percentage compressibility index. 
The percentage compressibility index was calculated according to following formula. 
%compressibility index= [1-V/V0] x 100 
Where V and VO are the volume of the sample after and before the standard tapping respectively. 
Each determination was made in triplicate. 
TABLE No –3: Limitations for Preformulation studies. 
 
UV-Visible Spectroscopy: 
Construction of Standard graph of Lopinavir: 
The Stock solution of Lopinavirwas prepared by accurately dissolving 100mg in 100ml 
of phosphate buffer pH 6.8. From this 10ml was taken and diluted up to 100ml with phosphate 
buffer pH 6.8 to get 100µg/ml solution. From this 10µg/ml solution was prepared by diluting 
10ml to 100ml with phosphate buffer pH 6.8. From this 2, 4, 6&8 to 10ml with phosphate 
buffer pH 6.8. Absorbance were measured at 258 nm and results were tabulated in table  
Preparation of tablets: 
Direct compression method: 
The conventional tablets of Lopinavirwere prepared by direct compression method. The drug 
powder and excipients were weighed and mixed and passed through the sieve no 40.the powder 
was fed manually into the die of 12 stage tablet punching machine and then compressed at 
proper compression force. 
 
S.N0 Angle of repose (θ) Carr’s index Type of flow 
1 <25 5-15 Excellent 
2 25-30 12-16 Good 
3 30-40 18-21 Passable 
4 - 23-35 Poor 
5 - 33-38 Very poor 
6 >40 >40 Extremely poor 
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Drug Content Estimation:  
Drug content in solid dispersions was estimated by weighing 100 mg of solid dispersion 
accurately and dissolved in 100 ml of Phosphate buffer pH6.8. The solution was filtered, diluted 
suitably and drug content was analyzed at 258nm by UV spectrophotometer. Each sample 
analyzed in triplicate. Actual drug content was calculated for all batches using the equation as 
follows: 
 
                                Actual Lopinavircontent in weighed quantity of solid dispersion 
Drug content (%) =  X 100 
                                            Theoretical amount of Lopinavir in Solid dispersion 
 
In vitro drug release studies: 
Preparation of dissolution media: 
Potassium Di-hydrogen Phosphate (0.2M):  
Dissolve 21.218g of Potassium hydrogen phosphate in water and dilute with water to 1000ml. 
Sodium Hydroxide (0.2M): 
Dissolve NaOH in water to produce a 40-60% w/v solution and allow to stand. Taking 
precautions to avoid absorption of CO2 siphon off the clear supernatant liquid and dilute with 
CO2 free water a suitable volume of liquid to contain 8gm of NaOH in 1000ml. 
Phosphate Buffer: 
Place 50ml of 0.2M potassium Dihydrogen phosphate in a 200ml volumetric flask, add 
the specific volume of 0.2M NaOH and then add water to volume. 
Dissolution rate determination: 
After estimating the drug content in solid dispersions, dissolution was performed to 
assess the release rate from dispersions. The dissolution was carried out in multi station (8) 
dissolution apparatus. It was automated and digital equipment. The entire dissolution was 
carried out at a temperature 37˚c and at 75 rpm for one hr. The dissolution medium (pH 6.8 
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phosphate buffer) was placed in basket-1. The pure drug, marketed formulation and the 
formulations with batch code F1,F2,F3,F4,F5,F6 in the baskets 2, 3, 4, 5, 6 and 7 respectively. 
The 8th basket is left for internal thermal probe, and it was filled with pH 6.8 phosphate buffer. 
The solid dispersions of corresponding weights calculated from content evaluation studies were 
introduced into respective baskets.  
5ml of samples were withdrawn at intervals of 5min, 10min, 15min, 20min, 30min, 
45min and 60min from each basket. After each withdrawal the same volume of fresh dissolution 
medium was introduced. All the samples were taken into a series of test tubes which are labeled 
properly to avoid confusion. The dissolution test apparatus was stopped. Similar procedure was 
carried out for remaining batches F7, F8 respectively. 
The absorbance of each series of test samples was recorded by using UV-Visible 
Spectrophotometer. Dilutions were also done in necessary cases and the dilution factor was 
noted down. And the values were given in tables  
 
 
 
 
 
 
Table -4:  Dissolution Monograph of Lopinavir 
Apparatus Speed Temperature Volume of 
Medium 
Medium Time Intervals For 
Withdrawn of Samples
Type-II 
(paddle type) 
75 rpm 37˚c 900ml pH 6.8 
Phosphate 
buffer 
5,10,15,20,30,45&60 
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EVALUATION TESTS: 
Hardness test: 
The apparatus used for finding hardness is Monsanto hardness tester. It consists of base 
containing plunger is taken in contact with the tablet and zero reading is taken. The upper 
plunger is forced against the spring by a thread belt tube until the tablet fractures the spring is 
compressed. For each batch three tablets were tested. 
The hardness range varies between 4-7 kg/cm2 
Friability test: 
The acceptable range for conventional compressed tablet is not less than 0.5% - 1.0%. 10 
pre weighed tablets are taken in a friability apparatus and it is rotated at 25rpm for 4 min. 
then tablets are collected and recheck the weight and the percentage friability was calculated 
by the formula. 
 
Weight variation test: 
Weight 20 tablets individually then find out the weight variation and percentage 
weight variation using the formula: 
Weight variation = average weight – individual weight of tablet 
 
 
Limitation: 
S. No Average weight Percentage difference 
1 Less than 130 mg ± 10% 
2 130mg – 324mg ± 7.5% 
3 More than 324 mg ±5.0% 
 
Disintegration test: 
To determine disintegration time of 6 tablets are placed in each tube and the basket is 
positioned in 1 it beaker of which similar to gastric fluid at 37 c ± 0.5 c. the system is placed 
at a frequency of 28 – 30 cycles / min. perforated plastic disc is placed in the tube, in each 
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tube on the top of the tablet. That imparts an abrasive erosion to tablet. A tablet must 
disintegrate when all the particles pass through the main screen with the time specified. 
Stability studies of the tablet: 
Stability of a formulation can be defined as the time from date on manufacture of the 
formulation until its chemical or biological activity is not less than a pre-determined level of 
labeled potency and its physical characteristic have not changed appreciably or deleteriously. 
Formulation and the development of a pharmaceutical product are not complete without 
proper stability analysis, carried out on it to assess the physical and chemical stability and the 
safety. The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of environment 
factor such as temperature, humidity and light enabling recommended storage condition, re-
test periods and shelf lives. 
Generally the observation of the rate at which the product degrades under normal room 
temperature requires a long time. To avoid the undesirable delay, the principle of accelerated 
stability studies is adopted. 
The international conference on harmonization (ICH) guideline titled “stability testing of 
new drug substance and product” (QIA) describes the stability test requirements for drug 
registrations application in the European Union, Japan and United States of America. ICH 
specifies the length of study and storage conditions.   
 Long term testing: 250c ± 20c/60% RH ± 5% for 12 months. 
 Accelerated testing: 400c ± 20c/ 75 % RH ± 5% for 6 months. 
 
Method: 
               The selected formulation were packed in tightly closed container were plugged with 
cotton and capped. they were then stored at 400c  ± 20c/ 75 % RH  ± 5% for 3 months in 
humidity chamber  and valuate for their physical appearance and drug solution were further 
scanned to observe any possible spectral changes T80% was calculated by using dissolution 
studies. 
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RESULTS AND DISCUSSION  
Standard Graph: 
Different concentrations of Lopinavir from 2 to 10µg/ml were prepared and the 
absorbance was taken at 258 nm against pH 6.8 Phosphate buffer and graph was plotted 
between concentration and absorbance. 
TABLE -5: 
 
S. No Concentration(µg/ml) Absorbance 
1. 0 0 
2. 2 0.127 
3. 4 0.233 
4. 6 0.402 
5. 8 0.515 
6. 10 0.642 
                                                                      
 
 
                                                                          FIG –6 
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FT-IR studies: 
FT-IR studies were conducted for Solid dispersions of Lopinavir to determine any 
interactions between drug and polymer. FT-IR spectrum for Lopinavir, PVP, and SLS, 
Mannitol, urea and different solid dispersions were obtained. The Charactestic peaks for 
Lopinavir, PVP, SLS, Mannitol and urea were identified and any notable shift in 
characteristic peaks were not observed in dispersion spectra. So that it was concluded that 
there was no interactions between drug and polymer.  
IR spectrum of Lopinavir, PVP, and SLS, Mannitol, urea and different solid dispersions were 
given below. 
Table - 6 
S.
no 
Type of 
bond 
Standard 
wave 
number 
Observed wave number 
Lopinavir LPNVR+
PVP 
LPNVR+ 
SLS 
LPNVR+ 
MANNITOL 
LPNVR+ 
UREA 
1 O-H 3400-3200 3373.61 3376.50 3375.34 3373.61 3399.65 
2 CO 1680-1630 1659.80 1652.90 1661.73 1661.69 1664.62 
3 NH 3500-3100 3293.56 3411.22 3488.84 3373.61 3461.38 
4 Aromatic 1600-1475 1527.67 1638.58 1524.34 1655.94 1508.38 
5 Alkene 1680-1600 1610.61 1697.41 - 1526.71 - 
6 C-H(CH2 
Bend) 
1465 1459.55 1446.66 1455.34 1455.41 1455.34 
7 C-O 1300-1000 1192.05 1293.31 1307.78 1306.82 1307.78 
8 aromatics 900-690 767.96 918.15 919.11 926.76 840.03 
9 C-H strch 2890-2690 2869.21 2872.10 - 2809.41 2870.17 
10 C-H bend 1640-1550 1307.78 1524.78 - - 1508.38 
11 N-H bend 1640-1550 1527.67 3411.22 1524.78 - 1521.75 
12 C-N 1350-1000 1307.78 1383.97 1307.78 - 1091.75 
13 Alkane 
(strch) 
3000-2850 2950.32 2953.12 2927.08 2907.48 - 
14 CH3 
(bend) 
1450-1375 1436.23 1422.55 1455.34 1465.95 - 
15 CH2 
(bend) 
1465 1449.55 1463.06 - - - 
16 S=O 1050 - - 1051.24 1084.99 - 
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FIGURE -7 IR SPECTRA OF LOPINAVIR 
 
FIGURE – 8 IR SPECTRA OF PVP 
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FIGURE – 9 IR SPECTRA OF MANNITOL 
 
FIGURE – 10 IR SPECTRA OF UREA 
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FIGURE – 11 IR SPECTRA OF SLS 
 
FIGURE – 12 IR SPECTRA OF LOPINAVIR WITH PVP 
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FIGURE - 13 IR SPECTRA OF LOPINAVIR WITH MANNITOL 
 
FIGURE -14 IR SPECTRA OF LOPINAVIR WITH UREA 
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FIGURE – 15 IR SPECTRA OF OPINAVIR WITH SLS 
 
PREFORMULATION STUDIES: 
Bulk density: 
The bulk density of formulations from F1-F8 was measured by the graduated cylinder. The 
bulk density was found in the range from 0.428 – 0.482 the results were tabulated in the table 
no-7. 
Tapped density: 
The tapped density of formulations from F1 – F8 was measured by the measuring cylinder. 
The tapped density was found in the range from 0.418 – 0.480 the results were tabulated in 
the table no-7 
Angle of repose of solid dispersed Lopinavir: 
Angle of repose of solid dispersed Lopinavir powders was evaluated by fixed funnel method. 
Acceptable range of angle of repose is 220 61 to 310 60’.all the formulations showed an angle 
of repose within the range as shown in table no -7 formulations F1 to F8 showed an angle of 
repose in the acceptable range, which indicates a good flow property. 
Percentage compressibility index: 
 The percentage compressibility index was determined by using the bulk density and 
tapped density. The experimental percentage compressibility index was found to be in range 
of 10.56 – 19.26%. The results were tabulated in the table no -7 
Percentage Drug content Estimation: 
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Amount of Lopinavir in formulations from F1-F8 was estimated by UV-spectroscopy and the 
results were found as follows: 
Table: 7 
 
 
EVALUATION STUDIES: 
Hardness test: 
Formulations was evaluated by using hardness tester .the hardness of the tablets was 
found in the range between 5.13 – 5.80 the results were tabulated in the following table -8 
Friability test: 
The tablets were evaluated by the Roche friability apparatus the acceptable range for 
conventional compressed tablet is not less than 0.5% - 1.0%.results are given in the Table -
8.In the above table all formulations are shows that the percentage friability ranges between 
0.5% - 1.0% so all the formulations are passes the test.   
Weight variation test: 
The formulations are present in the range with acceptable weight variations less than 5% the 
results were given in the table no -8  
Disintegration test:  
The disintegration time of the tablets was determined and the results were tabulated in the 
following table no -8 
 
Formulation 
code 
 
Bulk 
density 
g/cc 
Tapped 
density g/cc 
Angle of 
repose 
Compressibility 
index 
DRUG 
CONTENT 
% 
F1 0.428 0.435 260 35 15.23 88.79 
F2 0.464 0.459 280 49 16.42 78.14 
F3 0.482 0.480 300 18 19.26 89.91 
F4 0.423 0.418 260 51 15.86 86.98 
F5 0.430 0.440 250 31 10.56 97.17 
F6 0.458 0.465 290 58 18.64 73.99 
F7 0.412 0.418 280 29 16.12 80.13 
F8 0.473 0.463 290 38 18.41 75.74 
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Table: 8 
 
IN VITRO DRUG RELEASE STUDY: 
The release data obtained for F1-F8 formulations were tabulated in the following tables.  
Table - 9: In-vitro release of F1-F8 Formulations of Lopinavir solid dispersion. 
 
Time 
(min) 
Percentage drug released 
Pure 
Drug 
Marketed 
Drug 
F1 F2 F3 F4 F5 F6 F7 F8 
5 2.26 3.54 6.65 4.07 5.43 3.26 6.79 5.29 7.87 3.93 
10 8.34 9.13 13.48 9.53 8.99 6.94 9.54 12.12 14.3 7.9 
15 12.37 22.6 21.36 19.5 17.16 17.16 18.56 21.03 22.77 19.96 
20 15.27 40.78 43.89 35.4 37.88 38.37 39.54 39.5 46.06 41.11 
30 19.34 51.83 61.55 50.3 53.1 51.04 65.35 46.3 61.57 58.77 
45 26.79 64.8 76.35 63.2 70.6 63.41 89.81 58.8 80.46 73.58 
60 29.52 75.13 87.22 70.7 81.4 68.22 98.09 71.6 90.97 81.86 
 
In vitro drug release studies reveal that there is marked increase in dissolution rate of 
Lopinavir from all the solid dispersions when compared to pure drug itself. The increase in 
dissolution rate is in the order of PVP>MANNITOL>UREA>SLS. The dissolution rate of 
Lopinavir in solid dispersion was strongly dependent on the relative concentration of the 
carrier. As the concentration of the carrier in the solid dispersion increased, the dissolution 
rate also increased. Formulation containing 1:4 ratio of Drug: PVP (F5) showed the best 
release with a release of 98.09% as compared to 29.52% with the pure drug. 
S.no Formulation 
code 
Hardness 
kg/cm2 
Percentage 
friability 
Weight 
variation 
Disintegration 
time 
1 F1 5.13 0.55 % 352±0.67 5 min 20 sec 
2 F2 5.52 0.61 % 351±2.34 5 min 45 sec 
3 F3 5.20 0.63 %  352±2.21 6 min 34 sec 
4 F4 5.75 0.72 % 353±1.86 7 min 10 sec 
5 F5 5.15 0.59 %  350±3.90 6 min 15 sec 
6 F6 5.62 0.65 % 351±1.77 6 min 50 sec 
7 F7 5.28 0.68 % 352±2.03 7 min 45 sec 
8 F8 5.80 0.74 % 353±1.92 7 min 55 sec 
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                               Fig 16: In-Vitro Drug Release of LopinavirF1-F4 (1:2) 
 
Fig 17: In-Vitro Drug Release of LopinavirF5-F8 (1:4) 
Stability Studies  
The success of an effective formulation can be evaluated only through stability 
studies. The purpose of stability testing is to obtain a stable product which assures its safety 
and efficacy up to the end of shelf life at defined storage conditions and peak profile. 
Stability studies of optimized formulation (F1 and F8) of Lopinavir tablets were placed on 
plastic tubes containing desiccant and stored at conditions, such as at room temperature, oven 
temperature (40±2ºC and 75 ± 5%) and refrigerator (2-8ºC) for a period of 3 month. The 
tablets were evaluated for Mucoadhesive properties and in vitro drug release after 2, 4 and 6 
Results obtained were compared with data obtained for zero time at room temperature, oven 
(40±2ºC and humidity 75 ± 5%) and refrigerator condition. 
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TABLE -10 
 
 
Parameters 
1st month 2nd month 3rd month 
RT 40 °C RT 40 °C RT 40 °C 
Uniformity of weight 351 350 354 352 352 352 
Hardness 5.23 5.87 6.28 5.33 5.19 5.01 
Friability 0.51 0.47 0.27 0.54 0.67 0.66 
% drug content (%) 98.33 97.77 98.40 96.90 98.28 97.37 
Disintegration test (in mins) 6.20 5.42 5.50 6.12 6.24 5.36 
Cumulative % release 98.11 98.17 97.56 98.08 97.67 98.32 
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SUMMARY 
 Solubility of drug molecule is a significant factor that affects the dissolution rate and 
bioavailability. According to biopharmaceutical classification Lopinavir belongs to class II 
drug, acting as an antiretroviral drug of the protease inhibitor class. The major problem 
associated with this drug is its poor bioavailability because of its insolubility in water and 
reduced dissolution rate. So in order to improve the drug solubility the drug must be 
formulated as conventional tablets by solid dispersion technique using different polymers. 
Dissolution is the rate limiting step for poorly water soluble drugs. Lopinavir is one 
such drug. The use of Solid dispersion technique has increased the dissolution rate of the drug 
by 30-65%. The solid dispersions of Lopinavir were successfully formulated by solvent 
evaporation method using carriers like PVP, SLS, mannitol, and urea. In-vitro release studies 
reveal that there is marked increase in the dissolution rate of Lopinavir from all the solid 
dispersions when compared to the pure Lopinavir itself. Using all four polymers 8 different 
formulations are prepared using the ratio 1:2 and 1:4 All the eight formulations are then 
subjected to various characterization studies like, FT-IR, tablet evaluation studies, in-vitro 
drug release studies, and stability studies etc. 
Preformulation study is carried out, bulk density, tapped density, Angle of repose, 
percentage compressibility was found out and all values are within the acceptable limit. The 
dissolution studies indicating that solid dispersion showing maximum cumulative percentage 
drug release compared to unprocessed drug. Tablet evaluation tests like hardness (5.13 – 
5.80kg/cm2), Friability test (0.5% - 1.0 %.), weight variation, disintegration was complies 
with IP standards. In-vitro drug release studies shows release rate was in the order of 
F5>F7>F3>F1>F8>F6> F4> F2. The increase in dissolution rate is due to the presence of 
carrier and the order was found to be PVP>mannitol>urea>SLS. Thus, if we formulate the 
poorly water soluble drugs like Lopinavir as solid dispersions the dissolution rate of drug can 
be increased markedly and hence higher plasma levels can be achieved. 
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CONCLUSION 
 
In the present research work an attempt was made to develop solid dispersion Lopinavir 
by solvent evaporation method for improving the solubility and bioavailability of drug. From 
the experimental findings, it is concluded that: 
 Polyvinyl pyrrolidone is the better polymer than urea, SLS and Mannitol and is not 
producing any interaction with drug when compared with other formulations. 
 The percentage drug content in all formulations was found in the range of 73.99 to 
97.17 %. 
 All the solid dispersion showing better saturation cumulative drug release compared 
to pure Lopinavir. 
 The in-vitro drug release studies shows that all the formulation releasing maximum 
amount of drug within 60 min and formulation F5 showing maximum drug release. 
 The optimum drug to polymer ratio was found to be in F5 (1:4), depending on in-vitro 
drug release studies. There is a significant increase in drug release with increase in 
drug to polymer ratio. 
 The stability studies showed that the remaining drug content is within the limits at 
different temperature and humidity levels. 
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